10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1 to

FORM 10-Q

(Mark One)

þ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2015

Or

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Millennium Healthcare Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-55009	11-3229358
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

68 South Service Rd. Suite 100, Melville, NY 11747

(Address of principal executive offices) (Zip code)

516-628-5500

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days.  Yes ¨   No þ

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ   No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

Large accelerated filer          ¨	Accelerated filer                     ¨
Non-accelerated filer            ¨  (Do not check if a smaller reporting company)	Smaller reporting company    þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨   No þ

The number of shares of common stock, par value $0.0001 per share of Millennium Healthcare Inc. outstanding as of the close of business on November 10, 2015 were 664,512,001.

Explanatory Note

The purpose of this Amendment No. 1 to Millennium Healthcare Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, filed with the Securities and Exchange Commission on November 23, 2015 (the “Form 10-Q”), is solely to describe the partial assignment, amendment and further settlement of a promissory note held by an individual. This filing does not modify the original Form 10-Q except as specifically noted herein.

No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

MILLENNIUM HEALTHCARE INC.

TABLE OF CONTENTS

	Page
PART I - FINANCIAL INFORMATION
Item 1.    Consolidated Financial Statements	1
Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.    Quantitative and Qualitative Disclosures About Market Risk	38
Item 4.    Controls and Procedures	38
PART II - OTHER INFORMATION
Item 1.    Legal Proceedings	39
Item 1A. Risk Factors	39
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds	39
Item 3.    Defaults Upon Senior Securities	39
Item 4.    Mine Safety Disclosures	39
Item 5.    Other Information	39
Item 6.    Exhibits and Reports on Form 8-K	40
SIGNATURES	41

PART I FINANCIAL INFORMATION

ITEM 1   FINANCIAL STATEMENTS

MILLENNIUM HEALTHCARE INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	SEPTEMBER 30,			DECEMBER 31,
	2015			2014
ASSETS
CURRENT ASSETS
Cash	$	21,975		$	112,725
Accounts receivable, net of allowance for doubtful accounts of $8,450,000 and $3,000,000 at September 30, 2105 and December 31, 2014, respectively		403,037			5,193,634
Inventory		100,000			100,000
Prepaid expenses		67,874			617,355
Total current assets		592,886			6,023,714
Fixed assets, net		712,025			789,950
OTHER ASSETS
Security deposits		378,024			375,595
Intangible assets, net		34,271			54,833
Total other assets		412,295			430,428
TOTAL ASSETS	$	1,717,206		$	7,244,092
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued expenses	$	2,523,053		$	1,278,748
Current portion of notes payable, net of debt discounts of $-0- and $220,878, and original issue discounts of $36,364 and $106,504, respectively		3,654,564			2,862,836
Derivative liability		4,023			1,061,476
Liability for common stock to be issued		10,033,978			640,100
Liability for preferred stock to be issued		876,513			3,103,800
Total current liabilities		17,092,131			8,946,960
Preferred stock		337,445			337,500
Notes payable, net of current portion		142,000			350,000
TOTAL LIABILITIES		17,571,576			9,634,460
STOCKHOLDERS' (DEFICIT)
Preferred stock, $0.0001 par value, 15,000,000 shares authorized
Series A Preferred stock, $0.0001 par value, 1,000,000 shares authorized, 1,000,000 and 600,000 shares issued and outstanding, respectively		100			60
Series B Preferred stock, $0.0001 par value, 0 shares issued and outstanding, respectively		-			-
Series D Preferred stock, $0.0001 par value, 0 shares issued and outstanding, respectively		-			-
Series E Preferred stock, $0.0001 par value, 0 shares issued and outstanding, respectively		-			-
Series F Preferred stock, $0.0001 par value, 3,000,000 shares authorized, 0 and 550,000 shares issued and outstanding, respectively		-			-
Series G Preferred stock, $0.0001 par value, 100,000 shares authorized, 0 shares issued and outstanding respectively		-			-
Common stock, $0.0001 par value, 950,000,000 and 200,000,000 shares authorized, respectively 479,262,001 and 128,828,942 shares issued and outstanding, respectively		47,926			12,883
Additional paid in capital		86,219,100			77,427,977
Deferred compensation		(5,844,350	)		(3,453,027	)
Accumulated deficit		(96,277,146	)		(76,378,261	)
Total stockholders' deficit		(15,854,370	)		(2,390,368	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	1,717,206		$	7,244,092

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

1

MILLENNIUM HEALTHCARE INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	NINE MONTHS			NINE MONTHS			THREE MONTHS			THREE MONTHS
	ENDED			ENDED			ENDED			ENDED
	SEPTEMBER 30, 2015			SEPTEMBER 30, 2014			SEPTEMBER 30, 2015			SEPTEMBER 30, 2014
REVENUE	$	933,485		$	7,427,290		$	149,935		$	6,366,728
OPERATING EXPENSES
Payroll, consulting and professional fees		13,304,426			16,768,150			980,745			8,947,853
Rent		743,622			450,723			272,993			268,617
General and administrative		889,677			1,003,489			235,716			365,714
Depreciation and amortization		139,082			51,198			46,468			17,596
Cost of Devices		-			550,000			-			550,000
Bad debt expense		5,455,115			-			-			-
Total operating expenses		20,531,922			18,823,560			1,535,922			10,149,780
NET LOSS BEFORE OTHER INCOME (EXPENSE) AND PREFERRED		(19,598,437	)		(11,396,270	)		(1,385,987	)		(3,783,052	)
STOCK DIVIDENDS
OTHER INCOME (EXPENSE)
Interest expense		(2,727,498	)		(848,218	)		(280,795	)		(382,938	)
Gain (loss) on change in fair value of derivative liability		4,088,195			(782,288	)		36,210			345,496
Total other income (expense)		1,360,697			(1,630,506	)		(244,585	)		(37,442	)
NET (LOSS) BEFORE PREFERRED STOCK DIVIDNEDS		(18,237,740	)		(13,026,776	)		(1,630,572	)		(3,820,494	)
Preferred stock dividends		-			(79,355	)		-			(26,452	)
NET (LOSS)	$	(18,237,740	)	$	(13,106,131	)	$	(1,630,572	)	$	(3,846,946	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC & DILUTED		233,911,019			77,330,185			376,616,131			82,091,238
NET (LOSS) PER SHARE - BASIC & DILUTED	$	(0.08	)	$	(0.17	)	$	(0.00	)	$	(0.05	)

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

2

MILLENNIUM HEALTHCARE INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	NINE MONTHS			NINE MONTHS
	ENDED			ENDED
	SEPTEMBER 30, 2015			SEPTEMBER 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)	$	(18,237,740	)	$	(13,106,131	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		139,081			51,198
Non-cash interest		150,000			137,153
(Gain) loss on change in fair value of derivative		(4,088,197	)		782,288
Preferred stock dividend		-			79,872
Amortization of deferred compensation		4,263,489			984,212
Share based compensation		8,856,806			11,058,959
Provisions for doubtful accounts		5,455,115			-
Change in operating assets and liabilities
Prepaid expenses		549,481			(498,257	)
Accounts receivable		(664,518	)		(6,863,015	)
Inventory		-			(77,638	)
Accounts payable and accrued expenses		1,244,306			142,033
Total adjustments		15,905,564			5,796,805
Net cash used in operating activities		(2,332,176	)		(7,309,326	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposits		(2,429	)		(296,332	)
Acquisition of fixed assets		(40,595	)		(58,139	)
Disposition of fixed assets		-			13,378
Net cash used in investing activities		(43,024	)		(341,093	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of preferred and common stock for cash (including liability for shares to be issued)		1,014,950			8,445,950
Proceeds received from notes payable		1,423,500			1,893,218
Repayments of notes payable		(154,000	)		(2,626,420	)
Net cash provided by financing activities		2,284,450			7,712,748
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(90,750	)		62,329
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		112,725			115,645
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	21,975		$	177,974
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	-		$	168,883
Taxes	$	-		$	-
NON-CASH SUPPLEMENTAL INFORMATION:
Issuance of common stock for liability of stock to be issued	$	5,667,409		$	4,105,550
Issuance (cancellation) of preferred stock for liability of stock to be issued, net	$	(2,662,120	)	$	2,269,500
Derivative liability issued for debt discount	$	-		$	233,321
Deferred compensation paid through issuance of common stock and liability to issue common stock	$	-		$	2,643,000

 The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

3

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

NOTE 1- BASIS OF PRESENTATION AND BUSINESS DESCRIPTION

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2015 and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on April 15, 2015.

Millennium Healthcare Inc. (the “Company”), was formed in the State of Delaware on July 28, 1994 as Kirlin Holding Corp., changed its name to Zen Holding Corp. in July, 2008 and to Millennium Healthcare, Inc. on June 16, 2011.

The Company has currently launched its medical equipment and device business. In connection therewith the Company has entered into various agreements to become the nationwide distributor for various medical devices mainly focused on preventative and diagnostic testing and care including an oral diagnostic biopsy test, a heart health test and assessment device, and a medical testing device in the area of breast cancer.

The Company also provides physician practice administration and support with a current focus on physician practices specializing in cardiovascular and vascular procedures and provides support and services specializing in medical procedure billing and collections, medical procedure coding, call and message management, and emergency dispatch.

Going Concern

These consolidated financial statements are presented on the basis that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred operating losses for the past several years, has a working capital deficiency of $16,499,245 and a stockholders’ deficit of $15,854,370 as of September 30, 2015. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.  

4

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

Segment Information

The Company follows the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. As of September 30, 2015 and for the nine months ended September 30, 2015 and 2014, the Company operated in three segments as well as separately identifying the corporate overhead costs. The segments are as follows: Coding – this includes the coding, billing and telecommunications services of the Company; Vascular – this includes all vascular physician practice administration and support services; and Devices – this includes all services related to the medical device and equipment segment.

The Company’s chief financial officer reviews financial information presented on an entity level basis accompanied by disaggregated information about revenues by product type and certain information about geographic regions where appropriate for purposes of making operating decisions and assessing financial performance.

September 30, 2015	Coding		Device		Vascular		Corporate			Total
Segmented Operating Revenues	$	-	$	306,840	$	626,645	$	-		$	933,485
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		5,285		4,763,586		1,790,906		13,833,063			20,392,840
Depreciation and Amortization		-		95,569		23,843		19,670			139,082
Other (Income) Expense		-		-		3,218		(1,363,915	)		(1,360,697	)
Assets
Fixed Assets	$	-	$	649,185	$	11,706	$	51,134		$	712,025
Intangible Assets		-		-		34,271		-			34,271

5

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

September 30, 2014	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	3,596	$	5,915,419	$	1,508,275	$	-	$	7,427,290
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		3,717		1,111,259		909,647		16,747,739		18,772,362
Depreciation and Amortization		-		969		26,797		23,432		51,198
Other (Income) Expense		-		-		-		1,630,506		1,630,506
Assets
Fixed Assets	$	-	$	57,170	$	16,080	$	39,536	$	112,786
Intangible Assets		-		-		61,687		-		61,687

Generally, any item not related to one of our other segments would be included in the Corporate Column. This includes corporate overhead costs such as consulting fees, legal fees, and other professional fees including all common stock issued for services; and interest expenses, including all fair value measurements of warrants and fair value adjustments related to our derivative liability that have been charged to interest. The Company has determined it would be more appropriate to include a corporate column rather than develop an allocation to our other divisions as the Company has not determined allocation percentages.

Recently Issued Accounting Standards

The Financial Accounting Standards Board and the Securities Exchange commission have issued certain accounting standards updates and regulations that will become effective in subsequent periods. Management does not believe that any of those updates would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect in 2015 and 2014, and it does not believe that any of those pronouncements will have a significant impact on the Company’s consolidated financial statements at the time they become effective.

NOTE 2- PREFERRED STOCK - SERIES F AND SERIES G

 .

During 2015, the Company entered into Satisfaction Agreements and Releases with various Series F holders in which 700,000 shares of Series F preferred stock were surrendered and exchanged for 2,840,000 shares of the Company’s common stock. Further, 240,000 of these common shares were issued and 2,600,000 shares valued at $390,000 were recorded as a liability for common stock to be issued.

6

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

During 2015, the Company entered into a Satisfaction Agreement and Release with a Series G holder in which 75 shares of Series G preferred stock were surrendered and exchanged for 300,000 shares of the Company’s common stock.

In June 2015, the Company entered into a unified Satisfaction Agreement and Release with various Series F and Series G holders in which 2,300,000 shares of Series F preferred stock and 4,775 shares of Series G preferred stock were surrendered and exchanged for shares of the Company’s common stock. The terms of the Agreement call for a 10,500,000 block of common shares at settlement and for common stock “true-up” blocks issuable under certain terms over 36 months until the common stock issued has reached a total realized cash value of $18,000,000. As a result, 10,500,000 shares of common stock for the initial block were valued at $420,000 and recorded as a liability for stock to be issued and 100,000,000 shares of common stock in reserve were valued at $4,000,000 and also recorded as a liability for stock to be issued.

In September 2015, the Company entered into Global Settlement Agreements with various promissory note holders in which $751,000 in the aggregate of remaining outstanding note balances were settled and satisfied for shares of the Company’s common and Series G preferred stock. As a result, 636 shares of Series G preferred stock were valued at $434,833 and recorded as a liability for stock to be issued.

NOTE 3- NOTES PAYABLE, PREFERRED AND COMMON STOCK, AND WARRANTS

Promissory Notes

The Company entered into a short term $200,000 Promissory Note on September 18, 2014. The note is scheduled to mature with the completion of the Company’s next round of financing under certain terms. Interest on the note is fixed and stated at 20,000 shares of the Company’s restricted common stock. In May 2015 the note was settled for a cash and common stock combination totaling $350,000. The cash portion is for a total of $90,000 payable under certain terms. The stock portion is for 5,000,000 unrestricted common shares at settlement and for a common stock “true-up” issuable under certain terms until the combined total of cash repaid and common stock issued has reach a total value of $350,000. In June 2015 the cash portion of the settled note has been repaid and the remaining unissued common stock portion of the settled note has been valued at $260,000 and recorded as a liability for common stock to be issued.

7

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

In October 2014, the Company entered into a short term $250,000 Promissory Note with an individual. The note had a maturity of 30 days and interest on the note was fixed at 175,000 shares of common stock. During October 2014, the Company made a $40,000 payment on the note for an extension of the note’s maturity. In October of 2014, as an inducement to extend this note, the Company included interest at the rate of 10% of the outstanding principal per annum, and extended the note through October 9, 2015. During September 2015, the note and any accrued interest were settled with the Holder for 173 shares of preferred stock – Series G and with the Holder and all assignees combined for 2,000,000,000 shares of common stock.

In October 2014, the Company entered into a short term $450,000 Promissory Note with an individual. The note had a maturity of 60 days and interest on the note was fixed at 300,000 shares of common stock. In December of 2014, as an inducement to extend this note, the Company included interest at the rate of 10% of the outstanding principal per annum, and extended the note through October 14, 2015. During September 2015, the note and any accrued interest were settled with the Holder for 415 shares of preferred stock – Series G and with the Holder and all assignees combined for 1,750,000,000 shares of common stock.

In October 2014, the Company entered into a short term $250,000 Promissory Note with an individual. The note had a maturity of 60 days and interest on the note was 7% per annum. During December 2014, the Company repaid the note in its entirety.

In October 2014, the Company entered into a short term $100,000 Promissory Note with an individual. The note had a maturity of 90 days and repayment on the note was fixed at 103% and 100,000 shares of common stock at maturity. During October 2015, the note was amended and any accrued interest was settled with the holder for 65,000,000 shares of common stock (under certain terms as defined in the amendment) and all notes plus accrued interest with all assignees combined were settled for 23 shares of preferred stock – Series G and 115,000,000 shares of common stock.

In October 2014, the Company entered into a short term $40,000 Promissory Note with an individual. The note had a maturity of one year and interest on the note is fixed at 10% per annum. In May 2015, the note and any accrued interest were settled for 22,000,000 unrestricted shares of common stock.

In October 2014, the Company negotiated and completed a settlement and full satisfaction of certain promissory and demand notes. The settlements included the issuance of 4,600,000 shares of common stock during September 2014 and payments of $450,000 during October 2014.

8

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

In December 2014, the Company entered into a short term $205,000 Promissory Note with an entity. The note has a maturity of one year and interest on the note is fixed at 10% per annum. During January 2015, the Company made total repayments of $114,000 on the note. Certain portions of the note have been assigned under similar terms by the Holder. During September 2015, the note and any accrued interest were settled with the Holder for 48 shares of preferred stock – Series G and with the Holder and all assignees combined for 1,750,000,000 shares of common stock.

In December 2014, the Company issued a promissory note with a principal amount of $350,000 with 350,000 shares of Common Stock pursuant to a private placement.  The note matures in 36 months and interest on the note is fixed at 12% and provides for regularly scheduled interest payments which shall be made quarterly in arrears.  In addition, the Company agreed to pay to the placement agent a fee of 10% of the aggregate purchase price received by the Company and a warrant equal to 10% of the aggregate number of shares issued in the offering. The Company accrued fees of $35,000 and 35,000 warrants to the placement agent during 2014. The Company paid the accrued fees of $35,000 to the placement agent during February 2015.

In January 2015, the Company issued a promissory note with a principal amount of $300,000 with 300,000 shares of Common Stock to be issued pursuant to a private placement. The note mature in 36 months and interest on the note is fixed at 12% and provides for regularly scheduled interest payments which shall be made quarterly in arrears.  In addition, the Company agreed to pay to the placement agent a fee of 10% of the aggregate purchase price received by the Company. The Company paid $30,000 to the placement agent during February 2015.

In January 2015, the Company sold a $220,000 Promissory Note to an unrelated individual. The note has a maturity of one year and interest on the note is fixed at 10% per annum.

In February 2015, the Company sold a $170,000 Promissory Note to a related individual. The note has a maturity of one year and interest on the note is fixed at 10% per annum. In May 2015 the holder issued a notice of default to the Company and certain default provisions of the note were triggered. In June 2015 the holder further issued an extension letter to the Company extending the defaulted note to June 30, 2015. The Company is currently in negotiations with the holder and a third party to have the note purchased and assigned.

In February 2015, the Company sold Promissory Notes totaling $142,000 as a result of private placements. These notes mature in 36 months and interest on the note is fixed at 12% and provides for regularly scheduled interest payments which shall be made quarterly in arrears.  In addition, the Company agreed to pay to the placement agent a fee of 10% of the aggregate purchase price received by the Company and a warrant equal to 10% of the aggregate number of shares issued in the offering. The Company paid fees of $14,200 in cash and 14,200 warrants to the placement agent during 2015.

9

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

In May 2015, the Company sold a $160,000 Promissory Note with an entity. The note has a maturity date of January 29, 2016 and interest on the note is fixed at 10% per annum.

Promissory Notes - Convertible

The Company sold a convertible promissory note to an unrelated entity on November 10, 2014 for $440,000. The note has a term of six months and accrues interest at 18% per annum. At any time during the term, the holder may convert the outstanding balance into common shares at a fixed conversion price of $1.00 per share. In May 2015, the Company received a notice of default from the holder. The notice demanded acceleration of repayment. The Company does not believe the note is in default and is currently in negotiations with the holder and a third party to have the note purchased and assigned.

The Company sold a convertible promissory note to an unrelated entity on November 10, 2014 for $660,000. The note has a term of six months and accrues interest at 18% per annum. At any time during the term, the holder may convert the outstanding balance into common shares at a fixed conversion price of $1.00 per share. In June 2015, the Company received a notice of default from the holder. The notice demanded acceleration of repayment. The Company is addressing the default, and is currently in negotiations with the holder and a third party to have the note purchased and assigned.

The Company sold a convertible promissory note to an unrelated entity on August 11, 2015 for $15,000. The note has a term of twelve months and accrues interest at 18% per annum. At any time upon 10 days written notice to the holder, the Company may prepay the principal amount of the note and any accrued and unpaid interest in an amount equal to the sum of the outstanding principal amount and interest multiplied by 120%. At any time during the term, the holder may convert the outstanding balance at a conversion price equal to 60% of the lowest daily Volume Weighted Average Price (“VWAP”) of the 20 trading days prior to conversion (and as defined in the note) of the Company’s common stock.

Promissory Notes – Original Issue Discount

During September 2015, the Company issued original issue discount notes (“OID Notes”) to various individuals for an aggregate principal amount of $192,500 along with 218,750,000 shares of the Company’s common stock. The OID Notes mature in 12 months and were issued at an original issue discount of $175,000.  No regularly scheduled interest payments shall be made on the OID Notes.

10

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

Promissory Notes – Original Issue Discount Convertible

During 2014, the Company issued original issue discount convertible notes (the “OID Notes”) with an aggregate principal amount of $1,235,218 with warrants to acquire up to 823,530 shares of Common Stock at $1.00 per share as described below.  The OID Notes mature in 13 months and were issued at an original issue discount of $185,283.  No regularly scheduled interest payments shall be made on the OID Notes.  The OID Notes may be converted by the investors into the Company’s common stock at the lower of (i) $0.75 or (ii) 80% of the per share price of the Company’s equity securities sold in a future public offering.  The warrants give each investor, for five years from the date of issuance, the right to purchase the Company’s common stock at (i) $1.00 or (ii) 80% of the lowest per share price of the Company’s common stock sold by the Company in any future public offering, during the period that the investor’s OID Note is outstanding. The OID Notes and related warrants contain anti-dilution provisions. In addition, the Company agreed to pay to the placement agent a fee of 10% of the gross proceeds received by the Company and a warrant equal to 10% of the aggregate number of shares issuable upon conversion of the Notes at an exercise price equal to 110% of the warrant exercise price. The Company paid fees of $104,935 in cash and 164,706 warrants to the placement agent during 2014. The Company is currently in negotiations with the holders and a third party to have the notes purchased and assigned.

On June 26, 2015, the Company sold 18% Convertible Promissory Notes in the principal amount of $560,000 (“Notes”) pursuant to a Securities Purchase Agreement (the “SPA”) for an aggregate of $500,000. The purchase is to occur in three tranches with the first tranche of $200,000 as the initial funding and closing, the second tranche of $250,000 being funded and closed on the one month anniversary, and the third tranche of $50,000 being funded and closed on the two month anniversary, provided there is no event of default and certain other equity conditions are met.

The Notes mature in 12 months and accrue interest at a rate of 18% per annum.  No regularly scheduled interest payments shall be made on the Notes. At any time upon 10 days written notice to the Holder, the Company may prepay the principal amount of the Note and any accrued and unpaid interest in an amount equal to the sum of the outstanding principal amount and interest multiplied by 120%. The Notes may be converted by the investors into the Company’s common stock at a conversion price equal $0.02 or 60% of the lowest daily VWAP (as defined in the SPA) of the Company’s common stock.

11

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

During July 2015, the Holder converted $200,000 of the $224,000 note into 38,711,548 shares of the Company’s common stock. No subsequent tranches have closed or have been funded by the Holder.

Additionally, during July 2015, the Holder acquired certain promissory notes previously issued by the Company from other note holders in the aggregate principal amount of $350,000 and exchanged these notes for certain 18% Convertible Promissory Notes (“Exchange Notes”) of the Company pursuant to certain Exchange Agreements (“Exchange Agreements”).

The Exchange Notes mature in 12 months and accrue interest at a rate of 18% per annum. No regularly scheduled interest payments shall be made on the Exchange Notes. At any time upon 10 days written notice to the Holder, the Company may prepay the principal amount of the Exchange Note and any accrued and unpaid interest in amount equal to the sum of the outstanding principal amount and interest multiplied by 120%. The Exchange Notes may be converted by the investors into the Company’s common stock at a conversion price equal $0.02 or 60% of the lowest daily VWAP (as defined in the Exchange Agreement) of the Company’s common stock.

During July 2015, certain portions of the note have been assigned under similar terms by the Holder. The note assignees have collectively converted $175,790 of the $350,000 combined notes into shares of the Company’s common stock. No subsequent exchanges have closed or have been funded by the Holder.

Preferred Stock

The Company has amended their certificates of designation to authorize the issuance of 6 separate series of preferred stock.

September 30, 2015

Preferred Stock	Authorized Date	Issue Date	Number of Shares Issued/Outstanding		Par Value		Conversion to Common Stock
Series “A" (1)	June 14, 2011	June 2011		1,000,000	$	.0001	N/A
Series “B" (2)	October 2011	October 2011		0	$	.0001	1.50:1
Series “D” (3)	March 30, 2012	April 2012		0	$	.0001	30:1
Series “E” (4)	June 1, 2013	June 2013		0	$	.0001	65:1
Series “F” (5)	December 2, 2013	December 2013		0	$	.0001	N/A
Series “G” (6)	March 7, 2014	March 2014		0	$	.0001	N/A

12

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

(1) Issued 100,000 shares to the principal owners of Millennium Healthcare Solutions Inc. upon acquisition of the net assets of that company; and issued 900,000 to the officers of Millennium Healthcare Inc. 

(2) Issued to an unrelated third party in conversion of the Line of Credit. There are no shares issued and outstanding as of September 30, 2015.

(3) Issued to an unrelated third party in conversion of the Series B Preferred Stock and additional funds provided. There are no shares issued and outstanding as of September 30, 2015.

(4) Issued to an unrelated third party in conversion of the Series D Preferred Stock. Settlement and conversion completed with all shareholders. There are no shares issued and outstanding as of September 30, 2015.

(5) Issued to investors as part of a private offering. There are no shares issued and outstanding as of September 30, 2015.

(6) Issued to investors as part of a private offering and to former note holders as note settlements and satisfaction. There are no shares issued and outstanding as of September 30, 2015.

On December 19, 2013, the Company increased their authorized preferred stock from 5,000,000 shares to 15,000,000 shares.

Series A Preferred Stock. These shares are non-convertible, and have super voting rights of 200 to 1 versus the Common Stock. In June 2011, 100,000 shares of Series A Preferred Stock were issued to the principal owners of Millennium Healthcare Solutions Inc. upon the acquisition of the net assets of that company. In January 2012, the Company issued 100,000 shares, in December 2013, the Company issued 300,000 shares, in July 2014 the Company issued 100,000 shares and in March 2015 the Company issued 400,000 shares of Series A Preferred Stock to senior management of the Company. Each share of this preferred has 200 votes in matters where shareholder votes are required. These shares are not convertible and are not transferable and, accordingly, management has attributed a nominal value to these shares.

In March 2015, the Company filed an amendment to its Designation, Number, Voting Powers, Preferences and Rights of Series A Preferred Stock. With this amendment, the holders of Series A Preferred Stock vote together as a single class with common stock holders and any other class or series of shares entitled to vote with the common stock, with the holders of the Series A Preferred Stock being entitled to fifty-one percent (51%) of the total votes on all such matters regardless of the actual number of shares of Series A Preferred Stock then outstanding, and the holders of common stock and any other shares entitled to vote being entitled to their proportional share of the remaining 49% of the total votes based on their respective voting power.

13

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

On June 1, 2013, the Company amended the certificate of designation to authorize a Series E Preferred Stock. The Series E Preferred Stock is convertible into 65 shares of common stock for each preferred share at any time after June 1, 2014 and convert automatically on May 31, 2018, as well as providing for an annual dividend of $0.80 per share per year. Concurrent with the designation of the Series E Preferred Stock, the Company exchanged the 126,280 shares of Series D Preferred Stock into Series E Preferred Stock. The Company issued 3,384 additional shares of Series E Preferred Stock to holders as payment of $33,843 in accrued dividends during the year. Accrued dividends through December 31, 2013 were $25,936. In February 2014, the Company issued 2,594 shares of Series E Preferred Stock to holders as payment of the $25,936 in accrued dividends through December 31, 2013. Accrued dividends for the Series E Preferred Stock through September 30, 2014 were $26,452.

During November 2014, the Company entered into a series of settlement agreements with all holders of the Series E Preferred Stock. As a result, a final dividend payment of $75,000 was made, 8,596,770 common shares were issued in conversion and 5,000,000 common shares were issued in settlement. There are no Series E Preferred shares issued or outstanding nor any dividends accrued or payable at September 30, 2015.

The Company amended its certificate of designation in December 2013 to authorize a Series F Preferred Stock (“Series F”) which provides for a quarterly dividend of 10% of the Company's earnings before interest, taxes, depreciation and amortization ("EBITDA") and is payable on a quarterly basis, beginning after two quarters following the issue date. Holders are not entitled to receive any dividend from the Company after they have received an aggregate of $1.20 per share. Once holders receive an aggregate of $1.20 for each share held, all Series F shall expire and/or be redeemable for $1.

Series F is: (i) junior to any class or series of capital stock of the Company specifically ranking by its terms senior to any Series F Preferred Stock of whatever subdivision; (ii) prior to any class or series of capital stock of the Company hereafter created not specifically ranking by its terms senior to or on parity with any Series F of whatever subdivision; and (iii) on parity with any class or series of capital stock of the Company hereafter created specifically ranking by its terms on parity with the Series F Preferred Stock in each case as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

14

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

The Company sold 1,950,000 units and raised $1,950,000 under a private placement during 2013. The Company sold 1,050,000 units and raised $1,050,000 through March 31, 2014 for a total of 3,000,000 units sold and $3,000,000 raised for this private placement. Each unit consisted of one share of common stock and one share of Series F. As a result, 3,000,000 shares of Series F were to be issued, in which 550,000 shares were issued during 2013 and 2,450,000 shares valued at $1,356,500 were recorded as a liability for stock to be issued. Due to the redeemable nature of the Series F, the unit price was allocated between the Common stock and Series F and the Series F is recorded as a preferred stock liability in the accompanying consolidated financial statements for the Series F shares that have been issued. This private placement is closed and will have no future participation.

During 2015, the Company entered into Satisfaction Agreements and Releases with various Series F holders in which 700,000 shares in the aggregate of Series F preferred stock were surrendered and exchanged for 2,840,000 shares in the aggregate of the Company’s common stock. Further, 240,000 of these common shares were issued and 2,600,000 shares valued at $390,000 were recorded as a liability for common stock to be issued.

In March 2014, the Company amended the certificate of designation to authorize a Series G Preferred Stock. During the six months ended June 30, 2014, the Company sold 1,175 units for $1,000 per unit. Each unit consisted of 1,000 shares of common stock and 1 share of Series G preferred stock. Holders of Series G Preferred Stock shall be entitled to receive, along with the Series F Holders, an aggregate quarterly dividend of 10% of the Corporation’s earnings before interest, taxes depreciation and amortization (“EBITDA”) computed under the generally accepted accounting principles (“GAAP”). For purposes of allocating the 10% dividend proportionally to the Series F and G Preferred Holders, G Preferred Shares will be weighted and valued at 1,000 times that of Series F. Dividends on Series G Preferred Stock shall be payable on a quarterly basis, beginning after two quarters following the original issue date (“Issuance Date”). Holders Series G Preferred Stock shall not be entitled to receive any dividend from the Corporation once they have received an aggregate of $1,200 for every share of Series G Preferred Stock they hold.

Series G Preferred Stock shall rank: (i) junior to any class or series of capital stock of the Corporation specifically ranking by its terms senior to any Series G Preferred Stock of whatever subdivision (collectively, “Senior Securities”); (ii) prior to any class or series of capital stock of the Corporation hereafter created not specifically ranking by its terms senior to or on parity with any Series G Preferred Stock of whatever subdivision (collectively, “Junior Securities”); and (iii) on parity with any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms on parity with the Series G Preferred Stock (“Parity Securities”) in each case as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary (all such distributions being referred to collectively as “Distributions”).

15

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

The Company sold 4,920 units and raised $4,920,000 under a private placement through December 31, 2014. Each unit for this private placement consisted of one thousand shares of common stock and one share of Series G. As a result, 4,920 shares of Series G were to be issued, were valued at $1,747,300 and recorded as a liability for stock to be issued.

The Company sold 418 units and raised $418,000 under a private placement through September 30, 2015. Each unit for this private placement consisted of one thousand shares of common stock and one share of Series G. As a result, 418 shares of Series G were to be issued, were valued at $397,580 and recorded as a liability for stock to be issued.

See Note 2 for various settlements.

Common Stock

In April 2015, the Company filed a certificate of amendment with the Secretary of State of Delaware to increase the authorized common shares to 350,000,000 shares.

In July, 2015, the Company filed a certificate of amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 350,000,000 shares to 950,000,000 shares.

In November, 2015, the Company filed a certificate of amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 950,000,000 shares to 10,950,000,000 shares.

Various increases in authorized common shares in the preceding paragraphs have been approved by the holders of a majority of the voting power of the Company’s common stock.

The Company’s Board has approved up to a 5,000 to 1 reverse stock split.

The Company issued 6,500,000 shares of common stock for consulting and other services during the nine months ended September 30, 2015.

The Company entered into satisfaction, exchange and release agreements with certain Preferred Stock holders, in which the holders exchanged respective shares held of the Company’s Preferred Stock for shares of the Company’s common stock totaling 240,000 shares during the nine months ended September 30, 2015.

The Company entered into satisfaction and release agreements with certain warrant holders, in which the holders exchanged respective warrants held for shares of the Company’s common stock totaling 176,100,299 shares during the nine months ended September 30, 2015.

16

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

The Company entered into satisfaction and release agreements with certain note holders, in which the holders exchanged respective promissory notes held for shares of the Company’s common stock totaling 56,300,000 shares during the nine months ended September 30, 2015.

The Company entered into various settlement and release agreements with certain placement agents and others in which the agents and other parties received 5,308,376 shares of the Company’s common stock as full settlement for any disputes during the nine months ended September 30, 2015.

The Company authorized and approved the return and cancellation of an aggregate of 24,000,000 shares of common stock held by certain officers and directors of the Company and the issuance of three-year warrants to purchase in the aggregate 30,000,000 shares of common stock to these certain officers and directors. The warrants may be exercised on a cashless basis and contain other customary terms.

The Company issued in the aggregate 128,764,384 shares of common stock as a result of certain note holders converting certain convertible promissory notes into the Company’s common stock in accordance to the terms of the respective notes.

Warrants

During the years ended December 31, 2012 and 2013, the Company issued 9,760,000 warrants at exercise prices ranging from $.50 to $1.00 per share. During the twelve months ending December 31, 2014, the Company settled and cancelled 8,300,000 warrants at exercise prices ranging from $.50 to $1.00 per share. During the twelve months ending December 31, 2014, the Company issued 17,688,236 warrants at exercise prices ranging from $.13 to $3.00 per share. All of the warrants are vested and remain outstanding. The warrants have a weighted average price of $.12.

Consultant warrants provided for services to be rendered over a one-year period of time. The Company issued 200,000 consultant warrants during 2013. The Company issued 1,700,000 consultant warrants and cancelled 500,000 consultant warrants during 2014. Such warrants vest evenly over a one-year period by month. The Company has recorded this as a prepaid expense and will amortize through the conclusion of the contract.

The Company issued 823,530 warrants at an exercise price of $1.00 per share to certain convertible note holders. The Company agreed to pay the placement agent a commission of warrants equal to 10% of the aggregate number of shares issuable upon conversion of these convertible notes at an exercise price equal to 110% of the warrant exercise price. The Company issued 164,706 warrants to the placement agent during 2014.

17

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

The Company authorized and approved 12,000,000 warrants, with an exercise price of $0.25, for its executive officers during 2014.

The Company entered into a warrant settlement and exchange agreement with an existing warrant holder. As a result, the Company issued 3,000,000 warrants with an exercise price of $.16 and cancelled 2,000,000 warrants with exercise prices ranging from $.50 to $1.00 during 2014.

The Company entered into release agreements with two note and warrant holders. As a result, the Company cancelled 2,500,000 warrants with exercise prices ranging from $.50 to $1.00 during 2014.

The Company entered into a settlement agreement with a warrant holder. As a result, the Company cancelled 3,300,000 warrants with exercise price of $.50 during 2014.

The Company agreed to pay the placement agent of a private placement a fee of warrants equal to 10% of the aggregate number of shares issued in the offering. The Company issued 14,200 warrants to the placement agent during 2015.

The Company authorized and approved 60,000,000 warrants at an exercise price of $0.025 for its executive officers and employees during 2015.

The Company authorized and approved the return and cancellation of an aggregate of 24,000,000 shares of common stock held by certain officers and directors of the Company and the issuance of three-year warrants to purchase in the aggregate 30,000,000 shares of common stock to these certain officers and directors. The warrants may be exercised on a cashless basis and contain other customary terms.

The Company entered into a series of satisfaction agreements and releases with various holders of the Company’s warrants during 2015, pursuant to which holders exchanged warrants to purchase an aggregate of 1,560,000 shares of the Company’s common stock with exercise prices ranging from $.50 to $1.00 for an aggregate of 222,450,000 shares of the Company’s common stock.

As a result of the Company entering into certain promissory note assignment agreements, during July 2015 the Company entered into various amendment agreements with these former note holders for their existing warrants. As a result, the Company amended 607,843 warrants in the aggregate to an exercise price of $.10 along with certain other restated terms and amendments to the original agreements.

18

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

As of September 30, 2015 there were 77,602,436 warrants outstanding.

The Company used the black-scholes method to value the warrants, with the following inputs: volatility 422.67%; quarterly dividend percentage 0%; and discount rate of 0.95%.

NOTE 4- INCOME TAXES

The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the nine months ended September 30, 2015 and 2014 to the Company’s effective tax rate is as follows:

	Nine Months Ended
	September 30, 2015			September 30, 2014
U.S. federal statutory rate		-34.0	%		-34.0	%
State income tax, net of federal benefit		-6.0	%		-6.0	%
Permanent differences		-0.8	%		-0.8	%
Change in valuation allowance		40.8	%		40.8	%
Income Tax provision (benefit)		0.0	%		0.0	%

The benefit for income tax is summarized as follows:

	Nine Months Ended
	September 30, 2015			September 30, 2014
Federal:
Current	$	-		$	-
Deferred		(6,260,000	)		(4,561,000	)
State:
Current
Deferred		(1,079,000	)		(786,000	)
Change in valuation allowance		7,339,000			5,347,000
Income Tax provision (benefit)	$	-		$	-

19

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

As of September 30, 2015, the Company had approximately $67,000,000 of federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2030. Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.

The Company files U.S. federal and state of New York tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2011. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

NOTE 5- FAIR VALUE MEASUREMENTS

The Company adopted certain provisions of ASC Topic 820. ASC 820 defines fair value, provides a consistent framework for measuring fair value under generally accepted accounting principles and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

Level 1 inputs: Quoted prices for identical instruments in active markets.

Level 2 inputs: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 inputs: Instruments with primarily unobservable value drivers.

20

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

The following table represents the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2015:

	Level 1		Level 2		Level 3		Total
Cash	$	21,975	$	-	$	-	$	21,975
Total assets	$	21,975	$	-	$	-	$	21,975
Notes payable, net of debt discount and OID	$	-	$	-	$	3,796,564	$	3,796,564
Embedded conversion feature and derivative liability	$	-	$	-	$	4,023	$	4,023
Total liabilities	$	-	$	-	$	3,800,587	$	3,800,587

The following table represents the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2014:

	Level 1		Level 2		Level 3		Total
Cash	$	177,974	$	-	$	-	$	177,974
Total assets	$	177,974	$	-	$	-	$	177,974
Notes payable, net of debt discount and OID	$	-	$	-	$	1,515,444	$	1,515,444
Embedded conversion feature and derivative liability	$	-	$	-	$	3,045,185	$	3,045,185
Total liabilities	$	-	$	-	$	4,560,629	$	4,560,629

	For the Nine Months Ended		For the Nine Months Ended
	2015		2014
Total gain/(loss) from revaluation of derivatives included in earnings:	$	4,088,195	$	(782,288	)

21

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

The carrying amounts of our short and long term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

We calculated the fair value of the embedded conversion feature and derivative liability using the Black-Scholes option-pricing model with the following assumptions: Fair value of stock $0.001; exercise price $0.10 to $1.00; risk free interest rate 0.95%, term of 5 years; volatility rate of 422.67%; dividend yield of 0%.

The following tables provide reconciliations of beginning and ending balances at September 30, 2015:  

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Notes Payable			Embedded conversion feature and derivative liability			Total
September 30, 2015
Beginning balance		3,212,836			1,061,476			4,274,312
Transfers into Level 3		-			-			-
Transfers out of Level 3		-			-			-
Total gains or losses		-			-			-
included in earnings (or changes in net assets)		-			(4,088,195	)		(4,088,195	)
included in other comprehensive income		-			-			-
Purchases, issuances, sales, and settlements		-			-			-
Purchases		-			-			-
Issuances		1,945,805			-			1,945,805
Sales		-			-			-
Settlements		(1,362,077	)		3,030,742			1,668,665
Ending balance		3,796,564			4,023			3,800,587

22

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

NOTE 6- COMMITMENTS

In April 2014, the Company entered into a five year two month lease agreement in New York City, New York for executive offices of the Company, which requires an annual payment of approximately $283,000 for the first year and increases 3% per year subsequent thereto plus any increases in real estate taxes over the base year, as defined. The Company paid a security deposit of $259,402.

In April 2014, the Company entered into a five year lease agreement in Boynton Beach, Florida for the development of a new 30,000 square foot facility. The lease provides for first year rent of approximately $103,000 plus operating expenses of approximately $98,000 plus annual increases. The Company paid a security deposit of $36,099.

In March 2015, the Company vacated its Boynton Beach, Florida warehouse and storage facility and entered into a month to month operating agreement and provides for the following logistics and warehousing fees: $15 per incoming new pallet handling, $17 per pallet monthly storage and $1.67 logistics fee per unit sold. The Company is responsible for all shipping costs.

In June 2015, the Company has also vacated its Garden City, New York offices and has relocated to Melville, New York.

The Company no longer occupies any leased space. The Company is currently engaged in legal proceedings with former landlords regarding certain leased space the Company had previously occupied. The Company is currently in ongoing negotiations to settle such legal actions.

While obligated under certain non-cancelable operating leases, rental expense was accounted for on the straight-line method, in which the excess of recognized rent expense over scheduled lease payments was included in accounts payable and accrued expenses.

Rental expense charged to operations aggregated $743,622 and $450,723 for the nine months ended September 30, 2015 and 2014, respectively.

In July 2015, the Company entered into an asset purchase agreement with HealthPath, LLC and its WellPath System, which is a Health Information Exchange (HIE) system that can electronically move clinical information among different healthcare information systems while maintaining the meaning of the information being exchanged. Further in July 2015, the Company also entered a letter of intent to acquire the MedX Group, a Healthcare Information Technology (HIT) company, which offers an integrated suite of products that allow healthcare providers to share information across healthcare ecosystems.

23

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

Employment Agreements

The Company has entered into employment agreements and has amended employment agreements with additional and existing key management individuals in 2014. The Company has issued stock bonuses which vest over a one to three-year period to certain individuals. The unvested portion is reflected as deferred compensation, with the vested portion expensed as stock based compensation.

In January 2015 the Company entered into an employment agreement with a key management individual. The Company is to issue a stock bonus which vests over a three-year period. The unvested portion will be reflected as deferred compensation, with the vested portion expensed as stock based compensation. The individual is no longer employed by the Company and any deferred compensation has been fully amortized.

In June 2015 the Company entered into an employment agreement with a key management individual. As a result of this agreement, the Company is to issue equity compensation to that individual. The unvested portion will be reflected as deferred compensation, with the vested portion expensed as stock based compensation over a five-year period. The individual is no longer employed by the Company and any deferred compensation has been fully amortized.

In June 2015 the Company entered into an employment agreement with a key management individual. As a result of this agreement, the Company is to issue equity compensation to that individual. The unvested portion will be reflected as deferred compensation, with the vested portion expensed as stock based compensation over a five-year period.

In August 2015 the Company entered into an employment agreement with a key management individual. As a result of this agreement, the Company is to issue common stock options to that individual. The unvested portions will be reflected as deferred compensation, with the vested portions expensed as stock based compensation over a six-month and one-year period. The individual is no longer employed by the Company and any deferred compensation has been fully amortized.

NOTE 7- CREDIT RISK AND OTHER CONCENTRATIONS

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables. The Company places its cash with high credit quality financial institutions. At times, such cash and cash equivalents may exceed the FDIC insured limit of $250,000.

Accounts receivable, net of allowance, from two customers were $4,775,507, which accounted for approximately 92% of the total receivables at December 31, 2014.

24

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

Revenue from one customer was $76,140 and from another was $450,000, which accounted for approximately 8% and 48% of the total revenues respectively for the nine months ended September 30, 2015 and revenue from one customer was $1,350,000 and from another was $5,775,312, which accounted for approximately 18% and 78% of the total revenues, respectively for the nine months ended September 30, 2014.

NOTE 8- CONTINGENCIES

On August 11, 2014, as previously disclosed, LMARK Holding LLC (“LMARK”) and Cypress Drive Partners LLC (“Cypress”) (“Cypress and LMARK are collectively referred to as the “Members”) filed a summons’s and complaint in the United States District Court Eastern District of New York against the Company (the “Federal Action”). The complaint (among other allegations) alleges that the Members sought to convert their respective Series E Preferred Shares and the Company refused to honor their requests. The complaint asks that the court order the Company to issue 1,950,000 unrestricted shares of its common stock to the Members. The Complaint asserts claims for breach of contract and alleges that the Members were injured in an amount to be determined at trial but not less than $1,000,000. The Company denies these allegations.

On November 13, 2014, the Company, Cypress and LMARK entered into a Settlement Agreement. Pursuant to the Settlement Agreement, on or before November 20, 2014, the Company shall issue: 812,500 shares of unrestricted common stock to Cypress in full conversion of their 12,500 Series E Preferred Shares, (ii) 1,137,500 unrestricted shares of common stock to LMARK in full conversion of their 17,500 Series E Preferred Shares, (iii) 416,000 restricted shares of common stock to LMARK and (iv) 584,000 restricted shares of common stock to Cypress. The parties agreed to promptly file a Stipulation of Voluntary Dismissal with Prejudice of the Federal Action. The Company received a release (subject to the terms of the Settlement Agreement) from Cypress and LMARK including with respect to the claims in the Federal Action and the Company gave Cypress and LMARK a release (subject to the terms of the Settlement Agreement).

On August 12, 2014, as previously disclosed, Aquafina Design LLC whose purported members are Cypress and LMARK, filed a summons and complaint with the Supreme Court of the State of New York, county of Nassau (the “Aquafina Action”) asserting that it provided the Company with certain loans, and was issued (among other securities) 110,000 detachable warrants, with each warrant giving it the right to purchase 30 common shares, for a total of 3,300,000 common shares.  The complaint further asserts that Aquafina exercised all of its warrants on a cashless basis on March 5, 2014 and was entitled to receive 1,312,048 unrestricted common shares and that the Company has not issued such shares.  The complaint seeks compensatory damages for breach of contract in favor of Aquafina in an amount to be determined at trial, but not less than $1,088,990.  The Company denies these allegations.

25

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

On November 13, 2014, the Company and Aquafina entered into a Settlement Agreement. Pursuant to the Settlement Agreement, the Company agreed to issue 2,000,000 restricted shares of common stock on or before November 20, 2014, in full satisfaction of any and all issues set forth in the Settlement Agreement, including but not limited to any claims for cashless warrants or a preferred offering. The Company also received a release from Aquafina pursuant to which Aquafina released all claims set forth in the Aquafina Action (subject to the terms of the Settlement Agreement) and the parties agreed to promptly file a Stipulation of Discontinuance with Prejudice of the Aquafina Action. Pursuant to the Settlement Agreement the Company also gave Aquafina a release (subject to the terms of the Settlement Agreement).

The Company is currently engaged in several ongoing legal proceedings with certain landlords in New York, New Jersey and Florida regarding certain leased space the Company had previously occupied. The Company has made the decision to move to a virtual model for its Florida inventory warehousing and fulfillment, and has relocated its New York corporate offices. The company is currently in ongoing negotiations to settle such legal actions.

The Company is currently in ongoing litigation to settle certain claims regarding compensation with one of its suppliers. The Company is currently in ongoing negotiations to settle such legal actions.

NOTE 9- SUBSEQUENT EVENTS

Common Stock

See Note 3 relating to the increase in the number of authorized shares of common stock of the Company, par value $0.0001 per share from 950,000,000 shares to 10,950,000,000 shares.

Promissory Notes – Original Issue Discount

During October 2015, the Company issued an original issue discount note (“OID Note”) with an entity for a principal amount of $55,000 along with 62,500,000 shares of the Company’s common stock. The OID Note matures in 12 months and was issued at an original issue discount of $50,000.  No regularly scheduled interest payments shall be made on the OID Notes.

During November 2015, the Company issued an original issue discount note (“OID Note”) with an entity for a principal amount of $66,000 along with 75,000,000 shares of the Company’s common stock. The OID Note matures in 12 months and was issued at an original issue discount of $60,000.  No regularly scheduled interest payments shall be made on the OID Notes.

26

MILLENNIUM HEALTHCARE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015 AND 2014 (UNAUDITED)

Contingencies

In October 2015, a summons and notice of motion for summary judgement in lieu of complaint in the Supreme Court of the State of New York, County of New York was filed against the Company (the “Motion”). The Motion (among other allegations) requests an order granting the Plaintiffs summary judgements under various alleged notes aggregating $1,007,482 plus all additional accruing interest and costs of collection. The Motion asserts claims and alleges that the Company is in default under various promissory notes held by the Plaintiffs. The Company denies these allegations.

In October 2015, the Company received a notice of default from a holder of certain promissory notes. The notice demanded the timely satisfaction of a required quarterly interest payment under the terms of the notes. The Company is addressing the default, and is currently in negotiations with the holder and a third party to have the note purchased and assigned.

27

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

Some of the statements contained in this Form 10-Q that are not historical facts are "forward-looking statements" which can be identified by the use of terminology such as "estimates," "projects," "plans," "believes," "expects," "anticipates," "intends," or the negative or other variations, or by discussions of strategy that involve risks and uncertainties. We urge you to be cautious of the forward-looking statements, that such statements, which are contained in this Form 10-Q, reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors affecting our operations, market growth, services, products and licenses. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of the risks we face, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, our performance or achievements, or industry results, to differ materially from those contemplated by such forward-looking statements include, without limitation:

· Our ability to raise capital when needed and on acceptable terms and conditions;

· our future operating results;

· our business prospects;

· any contractual arrangements and relationships with third parties;

· the dependence of our future success on the general economy; and

· the adequacy of our cash resources and working capital.

All written and oral forward-looking statements made in connection with this Form 10-Q are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements. Except as may be required under applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements whether as a result more information, future events or occurrences.

Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Company Overview

The Company is a medical device and healthcare support and services company. The Company purchases, supplies and distributes revolutionary medical devices and equipment focused primarily on preventative care through early detection. The Company also provides physician practice administration with a current focus on physician practices specializing in cardiovascular procedures. In addition, the Company provides support and services specializing in medical procedure billing and collections, medical procedure coding, call and message management, and emergency dispatch. The marketplace for the Company’s products and services continues to be high quality physician offices, practices and facility locations with competent and caring doctors and staff.

Current Operations and Recent Developments

The Company is currently rolling out its medical equipment and device business. This business focuses on strategic alliances and partnerships with medical device companies that provide innovative medical devices that utilize cutting edge technology, are cost effective, and FDA cleared. Devices the Company elects to distribute are focused on preventative and diagnostic testing and care with the anticipation of detecting potential medical issues in their early stages yielding positive medical outcomes for patients. All of the products that the Company distributes have obtained necessary approvals and certifications and are reimbursable under current medical procedure billing codes. As the Company continues to rollout and grow this business, it continues to capitalize on secured network selling agreements with US based healthcare organization for the use of its medical devices within these organizations’ managed locations. The Company continues to work to fulfill these secured agreements during rollout, focusing on delivering the best possible customer service and support to its valued partners.

The Company anticipates meeting challenges and continued growth through fiscal 2015.  The Company intends to support its established distribution channels as well as introduce new sales partnerships throughout the coming year.  In addition to increasing sales of existing product offerings, the Company intends to research, develop and introduce new products, technologies and services to its customers.

The Company is at the very beginning of its growth cycle and like many emerging growth companies, it faces challenges.  These challenges range from the need for additional growth capital and qualified personnel, to managing market expectations, and supporting product inventory as demand increases.  The Company believes that as it meets and overcomes these various challenges, increased opportunities for growth can be realized.

During the first half of 2015 the Company has vacated its Boynton Beach, Florida warehouse and storage facility and relocated to a state of the art, third party warehousing, inventory and logistics facility located in Miami, Florida. This new location will be used to provide and manage complete inventory, logistics and distribution for the Company’s regional operations. In continuing the model, the Company has also vacated its Garden City, New York and New York City, New York offices and has relocated to a state of the art, true virtual office environment in Melville, New York. This new location will be used to provide executive, management and administrative offices for the Company’s regional operations.

The Company will continue with the placement and support of product through existing networks and channels through 2015, establishing a core foundation and penetration for existing products, with the anticipation of building upon that foundation and further enhancing and expanding upon products offered and networks serviced during the first half of 2016, focusing on the evaluation, implementation and placement of new products through new distribution channels, partners and strategic alliances. As the Company looks forward to this growth and expansion, and the further execution of an enhanced model, the Company is actively seeking the appointment of a new executive management team. The Company is also seeking to expand its Board of Directors. During June 2015, two Board of Directors of the Company stepped down and resigned from the Board in order to allow for the future appointment of additional industry leadership and expertise. During the first half of the year, the Company had appointed a new Chief Executive Officer in June 2015 and appointed a new President in August 2015. While the Board of Directors' efforts to do so were in line with the forward progress of the Company in the healthcare services and device industry, the new CEO and President ultimately were not aligned with the Board's goals for the Company. As such, during September 2015, both the newly appointed Chief Executive Officer and President of the Company resigned effective September 30, 2015. The Company’s former President resumed the role as interim President as the Company aggressively identifies and pursues viable candidates to take these positions. The addition of new executive leadership is anticipated to provide the Company with healthcare and market industry leadership as well as extensive executive management experience in transforming the Company from a distributor of medical devices to a technology-based company. This endeavor also includes acquiring companies that can immediately contribute to this process.

28

In connection with this model, the Company has already begun to gain traction and is under way with its acquisition strategy under a new executive management initiative. In July 2015, the Company entered into an Asset Purchase Agreement with HealthPath, LLC and its WellPath System, which is a Health Information Exchange (HIE) system that can electronically move clinical information among different healthcare information systems while maintaining the meaning of the information being exchanged. Further in July 2015, the Company also entered a Letter of Intent (LOI) to acquire the MedX Group, a Healthcare Information Technology (HIT) company, which offers an integrated suite of products that allow healthcare providers to share information across healthcare ecosystems.

The Company is re-focusing its efforts and streamlining its physician practice administration and support business. This business offers physician practice development, support and administration services for physician facilities and practices with a focus on vascular disorders. This group assists the physician and his/her practice in creating environments in which essential vascular access care is provided effectively and efficiently, with optimal outcomes for both the physician and the patient. As the Company focuses on an enhanced model and becoming a healthcare technology-based company, it begins to pull away from allocating resources and the further development of this business.

Critical Accounting Policies and Estimates: Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates.

While our significant accounting policies are more fully described in our financial statements, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.

Convertible Instruments: The Company reviews the terms of convertible debt and equity securities for indications requiring bifurcation, and separate accounting, for the embedded conversion feature. Generally, embedded conversion features where the ability to physical or net-share settle the conversion option is not within the control of the Company are bifurcated and accounted for as a derivative financial instrument. (See Derivative Financial Instruments below). Bifurcation of the embedded derivative instrument requires allocation of the proceeds first to the fair value of the embedded derivative instrument with the residual allocated to the debt instrument. The resulting discount to the face value of the debt instrument is amortized through periodic charges to interest expense using the Effective Interest Method.

Derivative Financial Instruments: The Company generally does not use derivative financial instruments to hedge exposures to cash-flow or market risks. However, certain other financial instruments, such as warrants or options to acquire common stock and the embedded conversion features of debt and preferred instruments that are indexed to the Company’s common stock, are classified as liabilities when either (a) the holder possesses rights to net-cash settlement or (b) physical or net share settlement is not within the control of the Company. In such instances, net-cash settlement is assumed for financial accounting and reporting, even when the terms of the underlying contracts do not provide for net-cash settlement. Such financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period.

29

Revenue Recognition: The Company recognizes revenues from the following sources:

Sales of medical devices are recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the buyer is fixed or determinable, and collectability is reasonable assured.

Healthcare support, management and administration services rendered to healthcare centers and physician practices are recognized when the services have been rendered.

Impairment of Long-Lived Assets: Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company performs a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

In December, 2013 management decided to initiate a strategic change in the business operations of the Company. In connection therewith, management decided to focus its future efforts on the development of its medical device distribution business and to phase out its existing businesses.

As a result, the Company has impaired its goodwill and other net intangible assets aggregating $4,046,826 which were acquired in acquisitions consummated in 2011.

Stock-Based Compensation:

The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring or in Conjunction with Selling, Goods or Services”. The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to expense and additional paid-in capital.

Results of Operations

Nine Months Ended September 30, 2015 Compared to Nine Months Ended September 30, 2014

Revenue

For the nine months ended September 30, 2015, the Company had total revenue of $933,485 as compared to revenue of $7,427,290 for the nine months ended September 30, 2014. Revenue decreased by $6,493,805 or 87.4% over prior period due to the Company launching its medical device business in 2014 and supporting its existing, established distribution channels as well as researching new products, technologies and services during 2015. Additionally, the Company is currently focusing on transforming the Company from a distributor of medical devices to a healthcare technology-based company. In connection with this re-focus, the Company is also currently looking to obtain and secure new executive management team members to bring additional industry experience and expertise in accomplishing the Company’s current goals. The Company is also further streamlining its physician practice administration and support business. As the Company focuses on becoming a healthcare technology-based company, it begins to pull away from allocating resources and the further development of this business. 2015 revenue consisted of $450,000 in revenue from physician practice administration and support, $-0- in revenue from medical coding and billing, $176,645 in call answering and emergency dispatch services performed and $306,840 in revenues from the distribution and placement of medical devices.

30

For the nine months ended September 30, 2014, the Company had total revenue of $7,427,290. 2014 revenue consisted of $1,350,000 in revenue from physician practice administration and support, $3,596 in revenue from medical coding and billing, $158,275 in revenue from call answering and emergency dispatch services performed and $5,915,419 in revenues from the distribution and placement of medical devices. The changes in our operating expenses from September 30, 2015 to September 30, 2014 are as follows:

Payroll, consulting, and professional fees

Payroll, consulting, and professional fees aggregated $13,304,426 for the nine months ended September 30, 2015 compared to $16,768,150 for the nine months ended September 30, 2014, a decrease of $3,463,724 or 20.7%. The decrease is primarily attributed to a decrease in the value of common stock issued in connection with various settlements as well as for decreases in professional services aggregating $2,994,441 from $13,673,979 to $10,679,538, resulting from a reduction in the issuance of shares to consultants and professionals for services rendered for investor and public relations, marketing and capital raising efforts and in the issuance of shares through various settlement agreements with former warrant holders, note holders and others. Additionally, professional fees increased $297,802 to $2,103,684 from $1,805,882 in 2014 resulting from fees related to the re-focusing of the Company’s business in 2015, including business professionals, investor and public relations initiatives and capital raising efforts. Payroll and related tax expenses for the nine months ended September 30, 2015 decreased $329,650 to $316,894 compared to $646,544 for the nine months ended September 30, 2014. This decrease is primarily due to the ceasing of operations and vacating of the Boynton Beach, FL location, the vacating of the New York, NY and the Garden City, NY locations and the resulting settlements with former employees. Legal and accounting fees combined for the nine months ended September 30, 2015 had a net decrease of $437,436 to $204,310 compared to $641,746 for the nine months ended September 30, 2014 due to the Company utilizing additional legal and accounting services in 2014 for support required with the launch of the device business and for SEC compliance for certain reporting requirements.

Rent

Rent expense for the nine months ended September 30, 2015 was $743,622 compared to $450,723 for the nine months ended September 30, 2014, an increase of $292,899 or 65.0%. The increase was the result of expenses related to the former corporate headquarters and related escalations, expenses related to previously occupied office space in New York, New York, and expenses related to previously occupied office/warehouse space in Boynton Beach, Florida during the first half of 2015, along with reserves established for ongoing negotiations to settle certain legal proceedings with former landlords. The Company has vacated its Boynton Beach, Florida warehouse and storage facility and relocated to a state of the art, third party warehousing, inventory and logistics facility located in Miami, Florida. This new location will be used to provide and manage complete inventory, logistics and distribution for the Company’s regional operations. Additionally, the Company has also vacated its Garden City, New York and New York City, New York offices and has relocated to a state of the art, true virtual office environment in Melville, New York. This new location will be used to provide executive, management and administrative offices for the Company’s regional operations. Although the Company is currently engaged in ongoing negotiations to settle certain legal proceedings with certain landlords, the Company anticipates a material reduction in rent the end of 2015 through first half of 2016.

General and administrative

General and administrative expenses aggregated $889,677 for the nine months ended September 30, 2015 compared to $1,003,489 for the nine months ended September 30, 2014, a decrease of $113,812 or 11.3%. The decrease is primarily attributable to $154,970 in insurance expense for the nine months ended September 30, 2015 compared to $168,387 for the nine months ended September 30, 2014, a decrease of $13,417 or 8.0%. The decrease was primarily due to reduction in coverages for our device division as well as physician practice management division for vascular services along with a reductions in overall business policy coverages; $184,769 in telephone and telecommunication expense for the nine months ended September 30, 2015 compared to $49,747 for the nine months ended September 30, 2014, an increase of $135,022 or 271.4%. These costs increased primarily due to expenses for voice, data, software and hosting usage along with related cloud, dashboard, portal access, datacenter and polling development/maintenance and expansion of infrastructure for the device business during 2015; $63,232 in travel, entertainment, meals and related expenses for the nine months ended September 30, 2015 compared to $112,479 for the nine months ended September 30, 2014, a decrease of $49,247 or 43.8%, The decrease is primarily due to the ceasing of operations and vacating of the Boynton Beach, FL location along with the re-focusing and transforming the Company from a distributor of medical devices to a technology-based company; and $486,707 in medical supplies, office and information technology expense for the nine months ended September 30, 2015 compared to $672,877 for the nine months ended September 30, 2014, a decrease of $186,170 or 27.7%. These costs decreased as the Company streamlines its physician practice management division and the purchase of medical supplies for that business and decreased levels of office and related technology/administration expenses primarily due to the ceasing of operations and the vacating of the Boynton Beach, FL location as well as the vacating of the New York City, NY and Garden City, NY locations.

31

Cost of devices

Cost of devices for the nine months ended September 30, 2015 aggregated $-0- from $550,000 or 100.0% from the nine months ended September 30, 2014. This is primarily due to the Company launching its device business in 2014 and focusing on customer and product service, support and logistics for previously placed devices with existing networks during 2015, along with a focus on healthcare technology. The Company had appointed and continues to seek industry leaders in assembling a new executive management team as the Company is transitioning under this direction from a distributor of medical devices to a healthcare technology-based company, which will include the research and discovery of merger and acquisition candidates that can immediately contribute to this process.

Depreciation and amortization

Depreciation and amortization expenses for the nine months ended September 30, 2015 aggregated $139,082 and increased $87,884 from $51,198 or 171.7% from the nine months ended September 30, 2014 primarily due to the acquisition of certain fixed assets and the re-class of certain devices for distribution formerly recorded in inventory.

Bad debt expense

The Company made a provision of $5,455,115 for bad debts for the nine months ended September 30, 2015. Although recognizing such a provision, the Company remains diligent in collection efforts and remains confident in the future collections of its receivables.

Other income (expense)

Net other income (expense) was $1,360,697 for the nine months ended September 30, 2015 compared to ($1,630,506) for the nine months ended September 30, 2014, an increase of $2,991,203. This decrease in expense is primarily attributable to the fair value adjustment related to the derivative liability of $4,870,483 offset by an increase in interest expense of $2,121,417 for the nine months ended September 30, 2015.

Income taxes

No provision for income taxes has been recorded as the Company has provided a full valuation allowance.

Net Loss

The net loss of the nine months ended September 30, 2015 was ($18,237,740) compared to the net loss of ($13,106,131) for the nine months ended September 30, 2014. The Company had a loss per weighted average common share outstanding of ($0.08) for the nine months ended September 30, 2015 compared to ($0.17) for the nine months ended September 30, 2014.

32

Three Months Ended September 30, 2015 Compared to Three Months Ended September 30, 2014

Revenue

For the three months ended September 30, 2015, the Company had total revenue of $149,935 as compared to revenue of $6,366,728 for the three months ended September 30, 2014. Revenue decreased by $6,216,793 or 97.7% over prior period primarily due to the Company launching its medical device business in 2014 and supporting its existing, established distribution channels as well as researching new products, technologies and services during 2015. Additionally, the Company is currently focusing on transforming the Company from a distributor of medical devices to a healthcare technology-based company. In connection with this re-focus, the Company is also currently looking to obtain and secure new executive management team members to bring additional industry experience and expertise in accomplishing the Company’s current goals. The Company is also further streamlining its physician practice administration and support business. As the Company focuses on becoming a healthcare technology-based company, it begins to pull away from allocating resources and the further development of this business. 2015 revenue consisted of $-0- in revenue from physician practice administration and support, $-0- in revenue from medical coding and billing, $57,885 in call answering and emergency dispatch services performed and $92,050 in revenues from the distribution and placement of medical devices.

For the three months ended September 30, 2014, the Company had total revenue of $6,366,728. 2014 revenue consisted of $450,000 in revenue from physician practice administration and support, $1,298 in revenue from medical coding and billing, $54,610 in revenue from call answering and emergency dispatch services performed and $5,860,820 in revenues from the distribution and placement of medical devices. The changes in our operating expenses from September 30, 2015 to September 30, 2014 are as follows:

Payroll, consulting, and professional fees

Payroll, consulting, and professional fees aggregated $980,745 for the three months ended September 30, 2015 compared to $8,947,853 for the three months ended September 30, 2014, a decrease of $7,967,108 or 89.0%. The decrease is primarily attributed to a decrease in the value of common stock issued in connection with various settlements as well as for professional services aggregating $7,047,916 from $7,719,485 to $671,569, resulting from a reduction in the issuance of shares to consultants and professionals for services rendered for investor and public relations, marketing and capital raising efforts and the issuance of shares through various settlement agreements with former warrant holders, note holders and others. Additionally, professional fees decreased $215,978 to $248,024 from $464,002 in 2014 resulting in the re-focusing of the Company’s business in 2015, including business professionals, investor and public relations initiatives and capital raising efforts. Payroll and related tax expenses for the three months ended September 30, 2015 decreased $375,409 for the three months ended September 30, 2014. This decrease is primarily due to the ceasing of operations and vacating of the Boynton Beach, FL location, the vacating of the New York, NY and the Garden City, NY locations and the resulting settlements with former employees. Legal and accounting fees combined for the three months ended September 30, 2015 had a net decrease of $327,806 to $79,840 compared to $407,646 for the three months ended September 30, 2014 due to the Company utilizing additional legal and accounting services in 2014 for support required with the launch of the device business and for SEC compliance for certain reporting requirements.

Rent

Rent expense for the three months ended September 30, 2015 was $272,993 compared to $268,617 for the three months ended September 30, 2014, an increase of $4,376 or 1.6%. The increase was the result of expenses related to the former corporate headquarters previously occupied, expenses related to previously occupied office space in New York, New York, and expenses related to previously occupied office/warehouse space in Boynton Beach, Florida during the first half of 2015, along with reserves established for ongoing negotiations to settle certain legal proceedings with former landlords. The Company has vacated its Boynton Beach, Florida warehouse and storage facility and relocated to a state of the art, third party warehousing, inventory and logistics facility located in Miami, Florida. This new location will be used to provide and manage complete inventory, logistics and distribution for the Company’s regional operations. Additionally, the Company has also vacated its Garden City, New York and New York City, New York offices and has relocated to a state of the art, true virtual office environment in Melville, New York. This new location will be used to provide executive, management and administrative offices for the Company’s regional operations. Although the Company is currently engaged in ongoing negotiations to settle certain legal proceedings with certain landlords, the Company is beginning to realize a material reduction in rent as a result of these vacancies.

33

General and administrative

General and administrative expenses aggregated $235,716 for the three months ended September 30, 2015 compared to $365,714 for the three months ended September 30, 2014, a decrease of $129,998 or 35.5%. The decrease is primarily attributable to $44,363 in insurance expense for the three months ended September 30, 2015 compared to $61,435 for the three months ended September 30, 2014, a decrease of $17,072 or 27.8%. The decrease was primarily due to reduction in coverages for our device division as well as physician practice management division for vascular services along with a reductions in overall business policy coverages; $56,798 in telephone and telecommunication expense for the three months ended September 30, 2015 compared to $15,363 for the three months ended September 30, 2014, an increase of $41,435 or 269.7%. These costs increased primarily due to expenses for voice, data, software and hosting usage along with related cloud, dashboard, portal access, datacenter and polling development/maintenance and expansion of infrastructure for device business during 2015; $17,096 in travel, entertainment, meals and related expenses for the three months ended September 30, 2015 compared to $55,331 for the three months ended September 30, 2014, a decrease of $38,235 or 69.1%. The decrease is primarily due to the ceasing of operations and vacating of the Boynton Beach, FL location along with the re-focusing and transforming the Company from a distributor of medical devices to a technology-based company; and $117,459 in medical supplies, office and information technology expense for the three months ended September 30, 2015 compared to $233,587 for the three months ended September 30, 2014, a decrease of $116,128 or 49.7%. These costs decreased as the Company streamlines its physician practice management division and the purchase of medical supplies for that business and decreased levels of office and related technology/administration expenses primarily due to the ceasing of operations and the vacating of the Boynton Beach, FL location as well as the vacating of the New York City, NY and Garden City, NY locations.

Cost of devices

Cost of devices for the three months ended September 30, 2015 aggregated $-0- from $550,000 or 100.0% from the three months ended September 30, 2014. This is primarily due to the Company launching its device business in 2014 and focusing on customer and product service, support and logistics for previously placed devices with existing networks during 2015, along with a focus on healthcare technology. The Company had appointed and continues to seek industry leaders in assembling a new executive management team as the Company is transitioning under this direction from a distributor of medical devices to a healthcare technology-based company, which will include the research and discovery of merger and acquisition candidates that can immediately contribute to this process.

Depreciation and amortization

Depreciation and amortization expenses for the three months ended September 30, 2015 aggregated $46,468 and increased $28,872 from $17,596 or 164.1% from the three months ended September 30, 2014 primarily due to the acquisition of certain fixed assets and the re-class of certain devices for distribution formerly recorded in inventory.

Other income (expense)

Net other income (expense) was ($244,585) for the three months ended September 30, 2015 compared to ($37,442) for the three months ended September 30, 2014, an increase of $207,143. This increase in expense is primarily attributable to the fair value adjustment related to the derivative liability of $309,286 along with an increase in interest expense of $102,143 for the three months ended September 30, 2015.

34

Income taxes

No provision for income taxes has been recorded as the Company has provided a full valuation allowance.

Net Loss

The net loss of the three months ended September 30, 2015 was ($1,630,572) compared to the net loss of ($3,846,946) for the three months ended September 30, 2014. The Company had a loss per weighted average common share outstanding of ($0.00) for the three months ended September 30, 2015 compared to ($0.05) for the three months ended September 30, 2014.

Liquidity and Capital Resources

We have a history of operating losses as we have focused our efforts on raising capital and maintaining our physician practice administration business and the rollout of our medical device business. The report of our independent auditors issued on our consolidated financial statements as of and for the year ending December 31, 2014 expresses substantial doubt about our ability to continue as a going concern. In 2012, we were successful in raising net proceeds of $693,500 through private placements and $1,270,000 through debt financing in order to fund the development and growth of our operations. During 2013, we were successful in raising net proceeds of $1,950,000 through private placements and $1,805,200 through debt financing in order to fund the development and growth of our operations. During 2014 we were successful in raising net proceeds of $5,970,000 through private placements and $3,893,218 through debt financing in order to fund the development and growth of our operations as well as the extinguishing of certain existing demand, promissory and original issue discount notes as they became due. During 2015, we were successful in raising net proceeds of $444,000 through private placements and $1,423,500 through debt financing in order to fund the development and growth of our operations. Our ability to continue as a going concern is dependent on our obtaining additional adequate capital to fund additional operating losses until we become profitable. If we are unable to obtain adequate capital, we could be forced to cease operations.

The following table presents a summary of our net cash provided by (used in) operating, investing and financing activities for September 30, 2015 and 2014: 

	Nine Months Ended September 30
	2015			2014
Net cash used in operating activities		(2,332,176	)	$	(7,309,326	)
Net cash used in investing activities		(43,024	)		(341,093	)
Net cash provided by financing activities		2,284,450			7,712,748
Net (decrease) increase in cash		(90,750	)	$	62,329

Cash flows for the nine months ended September 30, 2015 compared to September 30, 2014: For the nine months ended September 30, 2015, we incurred a net loss of $18,237,740. Net cash used in operating activities was $2,332,176, net cash used in investing activities was $43,024 and net cash provided by financing activities was $2,284,450. For the nine months ended September 30, 2014, we incurred a net loss of $13,106,131. Net cash used in operating activities was $7,309,326, net cash used in investing activities was $341,093 and net cash provided by financing activities was $7,712,748.

35

Working Capital Deficit Information - The following table presents a summary of our working capital deficit: 

Category	September 30, 2015			December 31, 2014
Current assets		592,886			6,023,714
Current liabilities		17,092,131			8,946,960
Working capital (deficit)	$	(16,499,245	)	$	(2,923,246	)

As of September 30, 2015, the Company had a working capital deficit of $16,499,245, compared to $2,923,246 at December 31, 2014, or an increase in working capital deficit of $13,575,999. For 2015, current assets had a net decrease of $5,430,828 primarily due to a decrease of $90,750 in cash, a decrease of $4,790,597 in accounts receivable related to the Company recognizing an increase in allowances for doubtful accounts of $5,450,000, in which, although recognizing such reserve, the Company remains diligent in collection efforts and remains confident in the future collections of its receivables, as well as a net decrease in prepaid expenses of $549,481 primarily related to the settlement and full amortization of compensation as a result of certain consulting agreements. Current liabilities had a net increase of $8,145,171 primarily related to an increase of $7,166,591 in liability for stock to be issued, as a result of various settlement agreements with former warrant holders, note holders and others, decrease in the fair value of the derivative liability related to warrants issued with notes payable in 2014 of $1,057,453 and an increase of $1,244,305 in accounts payable and accrued expense, along with an increase in current portion of notes payable of $791,728.

Funding Requirements: We expect to incur substantial expenses and generate ongoing operating losses for the foreseeable future as we prepare for the scale-up of inventory and commencement and ongoing development of our medical equipment and device business as well as maintaining the existing base of our physician practice administration and support business. If we are unable to raise an adequate amount of capital, however, we could be forced to curtail or cease operations. Our future capital uses and requirements depend on numerous forward-looking factors. These factors include the following:

-the time and expense needed to complete the procurement of inventory and successful roll-out of the medical equipment and device business;

-the expense associated with building a network of independent sales representatives to market the devices selected for distribution;

-the degree and speed of patient and physician acceptance of these devices and products and the degree to which third-party payors approve and pay for reimbursement; and

-the time and expense needed to complete the securing of additional days at existing location under contract and/or the securing of additional new physician practice facilities and locations under contract for our practice administration and support business.

The Company anticipates meeting challenges and continued growth through fiscal 2015.  The Company intends to support its established distribution channels as well as introduce new sales partnerships throughout the coming year.  In addition to increasing sales of existing product offerings, the Company intends to research, develop and introduce new products, technologies and services to its customers.

The Company will continue with the placement and support of product through existing networks and channels through 2015, establishing a core foundation and penetration for existing products, with the anticipation of building upon that foundation and further enhancing and expanding upon products offered and networks serviced during the first half 2016, focusing on the evaluation, implementation and placement of new products through new distribution channels, partners and strategic alliances. As the Company works toward future growth and the further execution of an enhanced model, the Company is actively seeking the appointment of a new executive management team. The Company is also seeking to expand its Board of Directors. The addition of new executive leadership is anticipated to provide the Company with healthcare industry leadership experience as well as extensive executive management experience in transforming the Company from a distributor of medical devices to a technology-based company. This endeavor also includes acquiring companies that can immediately contribute to this process.

36

The Company also continues its capital raising efforts through 2015 with increased exposure and awareness through more formalized investor and public relations, roadshows and the engaging of professional firms.

In view of these matters, realization of certain of the assets in the accompanying balance sheet is dependent upon our continued operations, which in turn is dependent upon our ability to meet our financial requirements, raise additional financing, and the success of our future operations.

Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling debt securities, if convertible, further dilution to our existing stockholders would result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings, collaboration agreements, debt financings or licensing arrangements.

If adequate funds are not available, we may be required to terminate, significantly modify or delay the development and launch of our businesses, reduce our planned commercialization efforts, or obtain funds through means that may require us to relinquish certain rights that we might otherwise seek to protect and retain. Further, we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable.

37

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Our independent accounting firm has not, nor is required, to perform any procedures to assess the effectiveness of management remediation efforts.

Evaluation of Disclosure Controls and Procedures.

Our Principal Executive Officer and Principal Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not believed to be effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding disclosure. The Company is growing and currently lacks documented procedures included documentation related to testing of processes, data validation procedures from the systems into the general ledger, testing of systems, validation of results, disclosure review, and other analytics. Furthermore, the Company lacked sufficient personnel to properly segregate duties. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Controls.

There were no changes in our internal controls over financial reporting during the fiscal quarter ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

38

PART II-OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.  However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the business. The Company is currently engaged in ongoing legal proceedings with certain landlords for space previously occupied, with certain suppliers/vendors, including compensation and with certain note holders requesting summary judgements as further described in the notes to financial statements. The Company is currently in ongoing negotiations to settle such legal actions.

ITEM 1A. RISK FACTORS

None.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

39

ITEM 6. EXHIBITS

Exhibit Number	Description of Exhibit
31.1	Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a)
31.2	Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a)
32.1	Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
32.2	Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002

EX-101.INS	XBRL INSTANCE DOCUMENT
EX-101.SCH	XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
EX-101.CAL	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
EX-101.DEF	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
EX-101.LAB	XBRL TAXONOMY EXTENSION LABELS LINKBASE
EX-101.PRE	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		MILLENNIUM HEALTHCARE INC.
DATE: November 30, 2015	By:	/s/ Dominick Sartorio
		Dominick Sartorio
		Chairman of the Board

DATE: November 30, 2015	By:	/s/ Anthony Urbano
		Anthony Urbano
		Chief Financial Officer

41

EX-31.1

Exhibit 31.1

Certifications

I, Dominick Sartorio, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of Millennium Healthcare Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 30, 2015

/s/ Dominick Sartorio

Dominick Sartorio

Chairman of the Board (Principal Executive Officer)

EX-31.2

Exhibit 31.2

Certifications

I, Anthony Urbano, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of Millennium Healthcare Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 30, 2015

/s/ Anthony Urbano

Anthony Urbano

Chief Financial Officer (Principal Financial  Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Millennium Healthcare Inc. (the “Company”) on Form 10-Q/A for the period ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 30, 2015

/s/ Dominick Sartorio

Dominick Sartorio

Chairman of the Board (Principal Executive Officer)

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Millennium Healthcare Inc. (the “Company”) on Form 10-Q/A for the period ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 30, 2015

/s/ Anthony Urbano

Anthony Urbano

Chief Financial Officer (Principal Financial  Officer)

XML

CONTINGENCIES (Details Textual) - USD ($)		1 Months Ended
	Mar. 05, 2014	Nov. 30, 2014	Nov. 20, 2014	Aug. 12, 2014	Aug. 11, 2014	Sep. 30, 2015	Dec. 31, 2014
Loss Contingencies [Line Items]
Common Stock, Shares, Issued						479,262,001	128,828,942
Series E Preferred Stock [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		8,596,770
Cypress Drive Partners LLC [Member]
Loss Contingencies [Line Items]
Common Stock, Shares, Issued			812,500
Stock Issued During Period, Shares, Restricted Stock Award, Gross			584,000
Cypress Drive Partners LLC [Member] | Series E Preferred Stock [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities			12,500
Aquafina Design LLC [Member]
Loss Contingencies [Line Items]
Shares Issued For Contingency	1,312,048
Stock Issued During Period, Shares, Restricted Stock Award, Gross			2,000,000
Warrants Issued For Contingency				110,000
Warrant Issued To Purchase Of Common share				3,300,000
Loss Contingency, Damages Paid, Value	$ 1,088,990
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				30
LMARK Holding LLC [Member]
Loss Contingencies [Line Items]
Shares Issued For Contingency					1,950,000
Loss Contingency, Damages Sought, Value					$ 1,000,000
Common Stock, Shares, Issued			1,137,500
Stock Issued During Period, Shares, Restricted Stock Award, Gross			416,000
LMARK Holding LLC [Member] | Series E Preferred Stock [Member]
Loss Contingencies [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities			17,500

XML

INCOME TAXES (Details)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Taxes [Line Items]
U.S. federal statutory rate	(34.00%)	(34.00%)
State income tax, net of federal benefit	(6.00%)	(6.00%)
Permanent differences	(0.80%)	(0.80%)
Change in valuation allowance	40.80%	40.80%
Income Tax provision (benefit)	0.00%	0.00%

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 4- INCOME TAXES

                                  The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the nine months ended September 30, 2015 and 2014 to the Company’s effective tax rate is as follows:

 

	Nine Months Ended
	September 30,			September 30,
	2015			2014
U.S. federal statutory rate		-34.0	%		-34.0	%
State income tax, net of federal benefit		-6.0	%		-6.0	%
Permanent differences		-0.8	%		-0.8	%
Change in valuation allowance		40.8	%		40.8	%
Income Tax provision (benefit)		0.0	%		0.0	%

The benefit for income tax is summarized as follows:

	Nine Months Ended
	September 30,		September 30,
	2015		2014
Federal:
Current	$	-	$	-
Deferred		(6,260,000)		(4,561,000)
State:
Current
Deferred		(1,079,000)		(786,000)
Change in valuation allowance		7,339,000		5,347,000
Income Tax provision (benefit)	$	-	$	-

As of September 30, 2015, the Company had approximately $67,000,000 of federal and state net operating loss carryovers (“NOLs”) which begin to expire in 2030. Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under regulations.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against the entire deferred tax asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be realized.

The Company files U.S. federal and state of New York tax returns that are subject to audit by tax authorities beginning with the year ended December 31, 2011. The Company’s policy is to classify assessments, if any, for tax and related interest and penalties as tax expense.

XML

FAIR VALUE MEASUREMENTS (Details 1)	9 Months Ended
	Sep. 30, 2015 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 4,274,312
Transfers into Level 3	0
Transfers out of Level 3	0
Total gains or losses	0
included in earnings (or changes in net assets)	(4,088,195)
included in other comprehensive income	0
Purchases, issuances, sales, and settlements	0
Purchases	0
Issuances	1,945,805
Sales	0
Settlements	1,668,665
Ending balance	3,800,587
Notes Payable [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	3,212,836
Transfers into Level 3	0
Transfers out of Level 3	0
Total gains or losses	0
included in earnings (or changes in net assets)	0
included in other comprehensive income	0
Purchases, issuances, sales, and settlements	0
Purchases	0
Issuances	1,945,805
Sales	0
Settlements	(1,362,077)
Ending balance	3,796,564
Embedded Conversion Feature And Derivative Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	1,061,476
Transfers into Level 3	0
Transfers out of Level 3	0
Total gains or losses	0
included in earnings (or changes in net assets)	(4,088,195)
included in other comprehensive income	0
Purchases, issuances, sales, and settlements	0
Purchases	0
Issuances	0
Sales	0
Settlements	3,030,742
Ending balance	$ 4,023

XML

FAIR VALUE MEASUREMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash	$ 21,975		$ 21,975		$ 177,974
Total assets	21,975		21,975		177,974
Notes payable, net of debt discount and OID	3,796,564		3,796,564		1,515,444
Embedded conversion feature and derivative liability	4,023		4,023		3,045,185
Total liabilities	3,800,587		3,800,587		4,560,629
Total gain/(loss) from revaluation of derivatives included in earnings:	36,210	$ 345,496	4,088,195	$ (782,288)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash	21,975		21,975		177,974
Total assets	21,975		21,975		177,974
Notes payable, net of debt discount and OID	0		0		0
Embedded conversion feature and derivative liability	0		0		0
Total liabilities	0		0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash	0		0		0
Total assets	0		0		0
Notes payable, net of debt discount and OID	0		0		0
Embedded conversion feature and derivative liability	0		0		0
Total liabilities	0		0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash	0		0		0
Total assets	0		0		0
Notes payable, net of debt discount and OID	3,796,564		3,796,564		1,515,444
Embedded conversion feature and derivative liability	4,023		4,023		3,045,185
Total liabilities	$ 3,800,587		$ 3,800,587		$ 4,560,629

XML

FAIR VALUE MEASUREMENTS (Details Textual)	9 Months Ended
	Sep. 30, 2015 $ / shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions Value Of Stock	$ 0.001
Fair Value Assumptions, Risk Free Interest Rate	0.95%
Fair Value Assumptions, Expected Term	5 years
Fair Value Assumptions, Expected Volatility Rate	422.67%
Fair Value Assumptions, Expected Dividend Rate	0.00%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions, Exercise Price	$ 1.00
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Assumptions, Exercise Price	$ 0.10

XML

COMMITMENTS (Details Textual)	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2015 $ / Warrants	Apr. 30, 2014 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Apr. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net, Total					$ 743,622	$ 450,723
Security Deposit			$ 378,024		378,024			$ 375,595
Operating Leases, Rent Expense			$ 272,993	$ 268,617	$ 743,622	$ 450,723
Area Of Facility As Per Lease Agreement		new 30,000 square foot facility
Lease Agreements [Member]
Operating Leased Assets [Line Items]
Warehouse Fees Per Pallet Monthly Storage | $ / Warrants	17
Logistics Fee Per Unit Sold | $ / Warrants	1.67
Executive Offices Agreement [Member]
Operating Leased Assets [Line Items]
Security Deposit		$ 259,402
Operating Lease Rental Payment Percentage		3.00%
Operating Leases, Future Minimum Payments, Next Rolling Twelve Months		$ 283,000
Art Distribution Facility [Member]
Operating Leased Assets [Line Items]
Security Deposit							$ 36,099
Operating Leases, Future Minimum Payments Receivable, Current		103,000
Operating Leases, Rent Expense		$ 98,000

XML

NOTES PAYABLE, PREFERRED AND COMMON STOCK, AND WARRANTS

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Long-term Debt [Text Block]

NOTE 3- NOTES PAYABLE, PREFERRED AND COMMON STOCK, AND WARRANTS

Promissory Notes

The Company entered into a short term $200,000 Promissory Note on September 18, 2014. The note is scheduled to mature with the completion of the Company’s next round of financing under certain terms. Interest on the note is fixed and stated at 20,000 shares of the Company’s restricted common stock. In May 2015 the note was settled for a cash and common stock combination totaling $350,000. The cash portion is for a total of $90,000 payable under certain terms. The stock portion is for 5,000,000 unrestricted common shares at settlement and for a common stock “true-up” issuable under certain terms until the combined total of cash repaid and common stock issued has reach a total value of $350,000. In June 2015 the cash portion of the settled note has been repaid and the remaining unissued common stock portion of the settled note has been valued at $260,000 and recorded as a liability for common stock to be issued.

In October 2014, the Company entered into a short term $250,000 Promissory Note with an individual. The note had a maturity of 30 days and interest on the note was fixed at 175,000 shares of common stock. During October 2014, the Company made a $40,000 payment on the note for an extension of the note’s maturity. In October of 2014, as an inducement to extend this note, the Company included interest at the rate of 10% of the outstanding principal per annum, and extended the note through October 9, 2015. During September 2015, the note and any accrued interest were settled with the Holder for 173 shares of preferred stock – Series G and with the Holder and all assignees combined for 2,000,000,000 shares of common stock.

 In October 2014, the Company entered into a short term $450,000 Promissory Note with an individual. The note had a maturity of 60 days and interest on the note was fixed at 300,000 shares of common stock. In December of 2014, as an inducement to extend this note, the Company included interest at the rate of 10% of the outstanding principal per annum, and extended the note through October 14, 2015. During September 2015, the note and any accrued interest were settled with the Holder for 415 shares of preferred stock – Series G and with the Holder and all assignees combined for 1,750,000,000 shares of common stock.

In October 2014, the Company entered into a short term $250,000 Promissory Note with an individual. The note had a maturity of 60 days and interest on the note was 7% per annum. During December 2014, the Company repaid the note in its entirety.

In October 2014, the Company entered into a short term $100,000 Promissory Note with an individual. The note had a maturity of 90 days and repayment on the note was fixed at 103% and 100,000 shares of common stock at maturity. During October 2015, the note was amended and any accrued interest was settled with the holder for 65,000,000 shares of common stock (under certain terms as defined in the amendment) and all notes plus accrued interest with all assignees combined were settled for 23 shares of preferred stock – Series G and 115,000,000 shares of common stock.

In October 2014, the Company entered into a short term $40,000 Promissory Note with an individual. The note had a maturity of one year and interest on the note is fixed at 10% per annum. In May 2015, the note and any accrued interest were settled for 22,000,000 unrestricted shares of common stock.

 

In October 2014, the Company negotiated and completed a settlement and full satisfaction of certain promissory and demand notes. The settlements included the issuance of 4,600,000 shares of common stock during September 2014 and payments of $450,000 during October 2014.

In December 2014, the Company entered into a short term $205,000 Promissory Note with an entity. The note has a maturity of one year and interest on the note is fixed at 10% per annum. During January 2015, the Company made total repayments of $114,000 on the note. Certain portions of the note have been assigned under similar terms by the Holder. During September 2015, the note and any accrued interest were settled with the Holder for 48 shares of preferred stock – Series G and with the Holder and all assignees combined for 1,750,000,000 shares of common stock.

In December 2014, the Company issued a promissory note with a principal amount of $350,000 with 350,000 shares of Common Stock pursuant to a private placement.  The note matures in 36 months and interest on the note is fixed at 12% and provides for regularly scheduled interest payments which shall be made quarterly in arrears.  In addition, the Company agreed to pay to the placement agent a fee of 10% of the aggregate purchase price received by the Company and a warrant equal to 10% of the aggregate number of shares issued in the offering. The Company accrued fees of $35,000 and 35,000 warrants to the placement agent during 2014. The Company paid the accrued fees of $35,000 to the placement agent during February 2015.

In January 2015, the Company issued a promissory note with a principal amount of $300,000 with 300,000 shares of Common Stock to be issued pursuant to a private placement. The note mature in 36 months and interest on the note is fixed at 12% and provides for regularly scheduled interest payments which shall be made quarterly in arrears.  In addition, the Company agreed to pay to the placement agent a fee of 10% of the aggregate purchase price received by the Company. The Company paid $30,000 to the placement agent during February 2015.

In January 2015, the Company sold a $220,000 Promissory Note to an unrelated individual. The note has a maturity of one year and interest on the note is fixed at 10% per annum.

In February 2015, the Company sold a $170,000 Promissory Note to a related individual. The note has a maturity of one year and interest on the note is fixed at 10% per annum. In May 2015 the holder issued a notice of default to the Company and certain default provisions of the note were triggered. In June 2015 the holder further issued an extension letter to the Company extending the defaulted note to June 30, 2015. The Company is currently in negotiations with the holder and a third party to have the note purchased and assigned.

In February 2015, the Company sold Promissory Notes totaling $142,000 as a result of private placements. These notes mature in 36 months and interest on the note is fixed at 12% and provides for regularly scheduled interest payments which shall be made quarterly in arrears.  In addition, the Company agreed to pay to the placement agent a fee of 10% of the aggregate purchase price received by the Company and a warrant equal to 10% of the aggregate number of shares issued in the offering. The Company paid fees of $14,200 in cash and 14,200 warrants to the placement agent during 2015.

In May 2015, the Company sold a $160,000 Promissory Note with an entity. The note has a maturity date of January 29, 2016 and interest on the note is fixed at 10% per annum.

Promissory Notes - Convertible

The Company sold a convertible promissory note to an unrelated entity on November 10, 2014 for $440,000. The note has a term of six months and accrues interest at 18% per annum. At any time during the term, the holder may convert the outstanding balance into common shares at a fixed conversion price of $1.00 per share. In May 2015, the Company received a notice of default from the holder. The notice demanded acceleration of repayment. The Company does not believe the note is in default and is currently in negotiations with the holder and a third party to have the note purchased and assigned.

The Company sold a convertible promissory note to an unrelated entity on November 10, 2014 for $660,000. The note has a term of six months and accrues interest at 18% per annum. At any time during the term, the holder may convert the outstanding balance into common shares at a fixed conversion price of $1.00 per share. In June 2015, the Company received a notice of default from the holder. The notice demanded acceleration of repayment. The Company is addressing the default, and is currently in negotiations with the holder and a third party to have the note purchased and assigned.

The Company sold a convertible promissory note to an unrelated entity on August 11, 2015 for $15,000. The note has a term of twelve months and accrues interest at 18% per annum. At any time upon 10 days written notice to the holder, the Company may prepay the principal amount of the note and any accrued and unpaid interest in an amount equal to the sum of the outstanding principal amount and interest multiplied by 120%. At any time during the term, the holder may convert the outstanding balance at a conversion price equal to 60% of the lowest daily Volume Weighted Average Price (“VWAP”) of the 20 trading days prior to conversion (and as defined in the note) of the Company’s common stock.

Promissory Notes – Original Issue Discount

During September 2015, the Company issued original issue discount notes (“OID Notes”) to various individuals for an aggregate principal amount of $192,500 along with 218,750,000 shares of the Company’s common stock. The OID Notes mature in 12 months and were issued at an original issue discount of $175,000.  No regularly scheduled interest payments shall be made on the OID Notes.

Promissory Notes – Original Issue Discount Convertible

During 2014, the Company issued original issue discount convertible notes (the “OID Notes”) with an aggregate principal amount of $1,235,218 with warrants to acquire up to 823,530 shares of Common Stock at $1.00 per share as described below.  The OID Notes mature in 13 months and were issued at an original issue discount of $185,283.  No regularly scheduled interest payments shall be made on the OID Notes.  The OID Notes may be converted by the investors into the Company’s common stock at the lower of (i) $0.75 or (ii) 80% of the per share price of the Company’s equity securities sold in a future public offering.  The warrants give each investor, for five years from the date of issuance, the right to purchase the Company’s common stock at (i) $1.00 or (ii) 80% of the lowest per share price of the Company’s common stock sold by the Company in any future public offering, during the period that the investor’s OID Note is outstanding. The OID Notes and related warrants contain anti-dilution provisions. In addition, the Company agreed to pay to the placement agent a fee of 10% of the gross proceeds received by the Company and a warrant equal to 10% of the aggregate number of shares issuable upon conversion of the Notes at an exercise price equal to 110% of the warrant exercise price. The Company paid fees of $104,935 in cash and 164,706 warrants to the placement agent during 2014. The Company is currently in negotiations with the holders and a third party to have the notes purchased and assigned.

On June 26, 2015, the Company sold 18% Convertible Promissory Notes in the principal amount of $560,000 (“Notes”) pursuant to a Securities Purchase Agreement (the “SPA”) for an aggregate of $500,000. The purchase is to occur in three tranches with the first tranche of $200,000 as the initial funding and closing, the second tranche of $250,000 being funded and closed on the one month anniversary, and the third tranche of $50,000 being funded and closed on the two month anniversary, provided there is no event of default and certain other equity conditions are met.

The Notes mature in 12 months and accrue interest at a rate of 18% per annum.  No regularly scheduled interest payments shall be made on the Notes. At any time upon 10 days written notice to the Holder, the Company may prepay the principal amount of the Note and any accrued and unpaid interest in an amount equal to the sum of the outstanding principal amount and interest multiplied by 120%. The Notes may be converted by the investors into the Company’s common stock at a conversion price equal $0.02 or 60% of the lowest daily VWAP (as defined in the SPA) of the Company’s common stock.

During July 2015, the Holder converted $200,000 of the $224,000 note into 38,711,548 shares of the Company’s common stock. No subsequent tranches have closed or have been funded by the Holder.

Additionally, during July 2015, the Holder acquired certain promissory notes previously issued by the Company from other note holders in the aggregate principal amount of $350,000 and exchanged these notes for certain 18% Convertible Promissory Notes (“Exchange Notes”) of the Company pursuant to certain Exchange Agreements (“Exchange Agreements”).

The Exchange Notes mature in 12 months and accrue interest at a rate of 18% per annum. No regularly scheduled interest payments shall be made on the Exchange Notes. At any time upon 10 days written notice to the Holder, the Company may prepay the principal amount of the Exchange Note and any accrued and unpaid interest in amount equal to the sum of the outstanding principal amount and interest multiplied by 120%. The Exchange Notes may be converted by the investors into the Company’s common stock at a conversion price equal $0.02 or 60% of the lowest daily VWAP (as defined in the Exchange Agreement) of the Company’s common stock.

During July 2015, certain portions of the note have been assigned under similar terms by the Holder. The note assignees have collectively converted $175,790 of the $350,000 combined notes into shares of the Company’s common stock. No subsequent exchanges have closed or have been funded by the Holder.

Preferred Stock

The Company has amended their certificates of designation to authorize the issuance of 6 separate series of preferred stock.

September 30, 2015

							Conversion
			Number				to
Preferred	Authorized	Issue	of Shares		Par		Common
Stock	Date	Date	Issued/Outstanding		Value		Stock
Series “A" (1)	June 14, 2011	June 2011		1,000,000	$	.0001	N/A
Series “B" (2)	October 2011	October 2011		0	$	.0001	1.50:1
Series “D” (3)	March 30, 2012	April 2012		0	$	.0001	30:1
Series “E” (4)	June 1, 2013	June 2013		0	$	.0001	65:1
Series “F” (5)	December 2, 2013	December 2013		0	$	.0001	N/A
Series “G” (6)	March 7, 2014	March 2014		0	$	.0001	N/A

(1) Issued 100,000 shares to the principal owners of Millennium Healthcare Solutions Inc. upon acquisition of the net assets of that company; and issued 900,000 to the officers of Millennium Healthcare Inc. 

(2) Issued to an unrelated third party in conversion of the Line of Credit. There are no shares issued and outstanding as of September 30, 2015.

(3) Issued to an unrelated third party in conversion of the Series B Preferred Stock and additional funds provided. There are no shares issued and outstanding as of September 30, 2015.

(4) Issued to an unrelated third party in conversion of the Series D Preferred Stock. Settlement and conversion completed with all shareholders. There are no shares issued and outstanding as of September 30, 2015.

(5) Issued to investors as part of a private offering. There are no shares issued and outstanding as of September 30, 2015.

(6) Issued to investors as part of a private offering and to former note holders as note settlements and satisfaction. There are no shares issued and outstanding as of September 30, 2015.  

On December 19, 2013, the Company increased their authorized preferred stock from 5,000,000 shares to 15,000,000 shares.

Series A Preferred Stock. These shares are non-convertible, and have super voting rights of 200 to 1 versus the Common Stock. In June 2011, 100,000 shares of Series A Preferred Stock were issued to the principal owners of Millennium Healthcare Solutions Inc. upon the acquisition of the net assets of that company. In January 2012, the Company issued 100,000 shares, in December 2013, the Company issued 300,000 shares, in July 2014 the Company issued 100,000 shares and in March 2015 the Company issued 400,000 shares of Series A Preferred Stock to senior management of the Company. Each share of this preferred has 200 votes in matters where shareholder votes are required. These shares are not convertible and are not transferable and, accordingly, management has attributed a nominal value to these shares.

In March 2015, the Company filed an amendment to its Designation, Number, Voting Powers, Preferences and Rights of Series A Preferred Stock. With this amendment, the holders of Series A Preferred Stock vote together as a single class with common stock holders and any other class or series of shares entitled to vote with the common stock, with the holders of the Series A Preferred Stock being entitled to fifty-one percent (51%) of the total votes on all such matters regardless of the actual number of shares of Series A Preferred Stock then outstanding, and the holders of common stock and any other shares entitled to vote being entitled to their proportional share of the remaining 49% of the total votes based on their respective voting power.

On June 1, 2013, the Company amended the certificate of designation to authorize a Series E Preferred Stock. The Series E Preferred Stock is convertible into 65 shares of common stock for each preferred share at any time after June 1, 2014 and convert automatically on May 31, 2018, as well as providing for an annual dividend of $0.80 per share per year. Concurrent with the designation of the Series E Preferred Stock, the Company exchanged the 126,280 shares of Series D Preferred Stock into Series E Preferred Stock. The Company issued 3,384 additional shares of Series E Preferred Stock to holders as payment of $33,843 in accrued dividends during the year. Accrued dividends through December 31, 2013 were $25,936. In February 2014, the Company issued 2,594 shares of Series E Preferred Stock to holders as payment of the $25,936 in accrued dividends through December 31, 2013. Accrued dividends for the Series E Preferred Stock through September 30, 2014 were $26,452.

During November 2014, the Company entered into a series of settlement agreements with all holders of the Series E Preferred Stock. As a result, a final dividend payment of $75,000 was made, 8,596,770 common shares were issued in conversion and 5,000,000 common shares were issued in settlement. There are no Series E Preferred shares issued or outstanding nor any dividends accrued or payable at September 30, 2015.

The Company amended its certificate of designation in December 2013 to authorize a Series F Preferred Stock (“Series F”) which provides for a quarterly dividend of 10% of the Company's earnings before interest, taxes, depreciation and amortization ("EBITDA") and is payable on a quarterly basis, beginning after two quarters following the issue date. Holders are not entitled to receive any dividend from the Company after they have received an aggregate of $1.20 per share. Once holders receive an aggregate of $1.20 for each share held, all Series F shall expire and/or be redeemable for $1.

Series F is: (i) junior to any class or series of capital stock of the Company specifically ranking by its terms senior to any Series F Preferred Stock of whatever subdivision; (ii) prior to any class or series of capital stock of the Company hereafter created not specifically ranking by its terms senior to or on parity with any Series F of whatever subdivision; and (iii) on parity with any class or series of capital stock of the Company hereafter created specifically ranking by its terms on parity with the Series F Preferred Stock in each case as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

The Company sold 1,950,000 units and raised $1,950,000 under a private placement during 2013. The Company sold 1,050,000 units and raised $1,050,000 through March 31, 2014 for a total of 3,000,000 units sold and $3,000,000 raised for this private placement. Each unit consisted of one share of common stock and one share of Series F. As a result, 3,000,000 shares of Series F were to be issued, in which 550,000 shares were issued during 2013 and 2,450,000 shares valued at $1,356,500 were recorded as a liability for stock to be issued. Due to the redeemable nature of the Series F, the unit price was allocated between the Common stock and Series F and the Series F is recorded as a preferred stock liability in the accompanying consolidated financial statements for the Series F shares that have been issued. This private placement is closed and will have no future participation.

During 2015, the Company entered into Satisfaction Agreements and Releases with various Series F holders in which 700,000 shares in the aggregate of Series F preferred stock were surrendered and exchanged for 2,840,000 shares in the aggregate of the Company’s common stock. Further, 240,000 of these common shares were issued and 2,600,000 shares valued at $390,000 were recorded as a liability for common stock to be issued.

In March 2014, the Company amended the certificate of designation to authorize a Series G Preferred Stock. During the six months ended June 30, 2014, the Company sold 1,175 units for $1,000 per unit. Each unit consisted of 1,000 shares of common stock and 1 share of Series G preferred stock. Holders of Series G Preferred Stock shall be entitled to receive, along with the Series F Holders, an aggregate quarterly dividend of 10% of the Corporation’s earnings before interest, taxes depreciation and amortization (“EBITDA”) computed under the generally accepted accounting principles (“GAAP”). For purposes of allocating the 10% dividend proportionally to the Series F and G Preferred Holders, G Preferred Shares will be weighted and valued at 1,000 times that of Series F. Dividends on Series G Preferred Stock shall be payable on a quarterly basis, beginning after two quarters following the original issue date (“Issuance Date”). Holders Series G Preferred Stock shall not be entitled to receive any dividend from the Corporation once they have received an aggregate of $1,200 for every share of Series G Preferred Stock they hold.

Series G Preferred Stock shall rank: (i) junior to any class or series of capital stock of the Corporation specifically ranking by its terms senior to any Series G Preferred Stock of whatever subdivision (collectively, “Senior Securities”); (ii) prior to any class or series of capital stock of the Corporation hereafter created not specifically ranking by its terms senior to or on parity with any Series G Preferred Stock of whatever subdivision (collectively, “Junior Securities”); and (iii) on parity with any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms on parity with the Series G Preferred Stock (“Parity Securities”) in each case as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary (all such distributions being referred to collectively as “Distributions”).

The Company sold 4,920 units and raised $4,920,000 under a private placement through December 31, 2014. Each unit for this private placement consisted of one thousand shares of common stock and one share of Series G. As a result, 4,920 shares of Series G were to be issued, were valued at $1,747,300 and recorded as a liability for stock to be issued.

The Company sold 418 units and raised $418,000 under a private placement through September 30, 2015. Each unit for this private placement consisted of one thousand shares of common stock and one share of Series G. As a result, 418 shares of Series G were to be issued, were valued at $397,580 and recorded as a liability for stock to be issued.

See Note 2 for various settlements.

Common Stock

In April 2015, the Company filed a certificate of amendment with the Secretary of State of Delaware to increase the authorized common shares to 350,000,000 shares.

In July, 2015, the Company filed a certificate of amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 350,000,000 shares to 950,000,000 shares.

In November, 2015, the Company filed a certificate of amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 950,000,000 shares to 10,950,000,000 shares.

Various increases in authorized common shares in the preceding paragraphs have been approved by the holders of a majority of the voting power of the Company’s common stock.

The Company’s Board has approved up to a 5,000 to 1 reverse stock split.

The Company issued 6,500,000 shares of common stock for consulting and other services during the nine months ended September 30, 2015.

The Company entered into satisfaction, exchange and release agreements with certain Preferred Stock holders, in which the holders exchanged respective shares held of the Company’s Preferred Stock for shares of the Company’s common stock totaling 240,000 shares during the nine months ended September 30, 2015.

The Company entered into satisfaction and release agreements with certain warrant holders, in which the holders exchanged respective warrants held for shares of the Company’s common stock totaling 176,100,299 shares during the nine months ended September 30, 2015.

The Company entered into satisfaction and release agreements with certain note holders, in which the holders exchanged respective promissory notes held for shares of the Company’s common stock totaling 56,300,000 shares during the nine months ended September 30, 2015.

The Company entered into various settlement and release agreements with certain placement agents and others in which the agents and other parties received 5,308,376 shares of the Company’s common stock as full settlement for any disputes during the nine months ended September 30, 2015.

The Company authorized and approved the return and cancellation of an aggregate of 24,000,000 shares of common stock held by certain officers and directors of the Company and the issuance of three-year warrants to purchase in the aggregate 30,000,000 shares of common stock to these certain officers and directors. The warrants may be exercised on a cashless basis and contain other customary terms.

The Company issued in the aggregate 128,764,384 shares of common stock as a result of certain note holders converting certain convertible promissory notes into the Company’s common stock in accordance to the terms of the respective notes.

Warrants 

During the years ended December 31, 2012 and 2013, the Company issued 9,760,000 warrants at exercise prices ranging from $.50 to $1.00 per share. During the twelve months ending December 31, 2014, the Company settled and cancelled 8,300,000 warrants at exercise prices ranging from $.50 to $1.00 per share. During the twelve months ending December 31, 2014, the Company issued 17,688,236 warrants at exercise prices ranging from $.13 to $3.00 per share. All of the warrants are vested and remain outstanding. The warrants have a weighted average price of $.12.

Consultant warrants provided for services to be rendered over a one-year period of time. The Company issued 200,000 consultant warrants during 2013. The Company issued 1,700,000 consultant warrants and cancelled 500,000 consultant warrants during 2014. Such warrants vest evenly over a one-year period by month. The Company has recorded this as a prepaid expense and will amortize through the conclusion of the contract.

The Company issued 823,530 warrants at an exercise price of $1.00 per share to certain convertible note holders. The Company agreed to pay the placement agent a commission of warrants equal to 10% of the aggregate number of shares issuable upon conversion of these convertible notes at an exercise price equal to 110% of the warrant exercise price. The Company issued 164,706 warrants to the placement agent during 2014.

The Company authorized and approved 12,000,000 warrants, with an exercise price of $0.25, for its executive officers during 2014.

The Company entered into a warrant settlement and exchange agreement with an existing warrant holder. As a result, the Company issued 3,000,000 warrants with an exercise price of $.16 and cancelled 2,000,000 warrants with exercise prices ranging from $.50 to $1.00 during 2014.

The Company entered into release agreements with two note and warrant holders. As a result, the Company cancelled 2,500,000 warrants with exercise prices ranging from $.50 to $1.00 during 2014.

The Company entered into a settlement agreement with a warrant holder. As a result, the Company cancelled 3,300,000 warrants with exercise price of $.50 during 2014.

The Company agreed to pay the placement agent of a private placement a fee of warrants equal to 10% of the aggregate number of shares issued in the offering. The Company issued 14,200 warrants to the placement agent during 2015.

The Company authorized and approved 60,000,000 warrants at an exercise price of $0.025 for its executive officers and employees during 2015.

The Company authorized and approved the return and cancellation of an aggregate of 24,000,000 shares of common stock held by certain officers and directors of the Company and the issuance of three-year warrants to purchase in the aggregate 30,000,000 shares of common stock to these certain officers and directors. The warrants may be exercised on a cashless basis and contain other customary terms.

The Company entered into a series of satisfaction agreements and releases with various holders of the Company’s warrants during 2015, pursuant to which holders exchanged warrants to purchase an aggregate of 1,560,000 shares of the Company’s common stock with exercise prices ranging from $.50 to $1.00 for an aggregate of 222,450,000 shares of the Company’s common stock.

As a result of the Company entering into certain promissory note assignment agreements, during July 2015 the Company entered into various amendment agreements with these former note holders for their existing warrants. As a result, the Company amended 607,843 warrants in the aggregate to an exercise price of $.10 along with certain other restated terms and amendments to the original agreements.

As of September 30, 2015 there were 77,602,436 warrants outstanding.

The Company used the black-scholes method to value the warrants, with the following inputs: volatility 422.67%; quarterly dividend percentage 0%; and discount rate of 0.95%.

XML

CREDIT RISK AND OTHER CONCENTRATIONS (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 250,000
Allowance for Doubtful Accounts Receivable	8,450,000		$ 3,000,000
One Customer [Member] | Sales Revenue, Goods, Net [Member]
Concentration Risk [Line Items]
Sales Revenue, Goods, Net	$ 76,140	$ 1,350,000
Concentration Risk, Percentage	8.00%	18.00%
Two Customers [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Allowance for Doubtful Accounts Receivable			$ 4,775,507
Total Receivable Percentage			92.00%
Two Customers [Member] | Sales Revenue, Goods, Net [Member]
Concentration Risk [Line Items]
Sales Revenue, Goods, Net	$ 450,000	$ 5,775,312
Concentration Risk, Percentage	48.00%	78.00%

XML

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash	$ 21,975	$ 112,725
Accounts receivable, net of allowance for doubtful accounts of $8,450,000 and $3,000,000 at September 30, 2105 and December 31, 2014, respectively	403,037	5,193,634
Inventory	100,000	100,000
Prepaid expenses	67,874	617,355
Total current assets	592,886	6,023,714
Fixed assets, net	712,025	789,950
OTHER ASSETS
Security deposits	378,024	375,595
Intangible assets, net	34,271	54,833
Total other assets	412,295	430,428
TOTAL ASSETS	1,717,206	7,244,092
CURRENT LIABILITIES
Accounts payable and accrued expenses	2,523,053	1,278,748
Current portion of notes payable, net of debt discounts of $-0- and $220,878, and original issue discounts of $36,364 and $106,504, respectively	3,654,564	2,862,836
Derivative liability	4,023	1,061,476
Liability for common stock to be issued	10,033,978	640,100
Liability for preferred stock to be issued	876,513	3,103,800
Total current liabilities	17,092,131	8,946,960
Preferred stock	337,445	337,500
Notes payable, net of current portion	142,000	350,000
TOTAL LIABILITIES	17,571,576	9,634,460
STOCKHOLDERS' (DEFICIT)
Common stock, $0.0001 par value, 950,000,000 and 200,000,000 shares authorized, respectively 479,262,001 and 128,828,942 shares issued and outstanding, respectively	47,926	12,883
Additional paid in capital	86,219,100	77,427,977
Deferred compensation	(5,844,350)	(3,453,027)
Accumulated deficit	(96,277,146)	(76,378,261)
Total stockholders' deficit	(15,854,370)	(2,390,368)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,717,206	7,244,092
Series A Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT)
Preferred stock value	100	60
Series B Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT)
Preferred stock value	0	0
Series D Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT)
Preferred stock value	0	0
Series E Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT)
Preferred stock value	0	0
Series F Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT)
Preferred stock value	0	0
Series G Preferred Stock [Member]
STOCKHOLDERS' (DEFICIT)
Preferred stock value	$ 0	$ 0

XML

BASIS OF PRESENTATION AND BUSINESS DESCRIPTION

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

NOTE 1- BASIS OF PRESENTATION AND BUSINESS DESCRIPTION

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2015 and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on April 15, 2015.

Millennium Healthcare Inc. (the “Company”), was formed in the State of Delaware on July 28, 1994 as Kirlin Holding Corp., changed its name to Zen Holding Corp. in July, 2008 and to Millennium Healthcare, Inc. on June 16, 2011.

The Company has currently launched its medical equipment and device business. In connection therewith the Company has entered into various agreements to become the nationwide distributor for various medical devices mainly focused on preventative and diagnostic testing and care including an oral diagnostic biopsy test, a heart health test and assessment device, and a medical testing device in the area of breast cancer.

The Company also provides physician practice administration and support with a current focus on physician practices specializing in cardiovascular and vascular procedures and provides support and services specializing in medical procedure billing and collections, medical procedure coding, call and message management, and emergency dispatch.

Going Concern

These consolidated financial statements are presented on the basis that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred operating losses for the past several years, has a working capital deficiency of $16,499,245 and a stockholders’ deficit of $15,854,370 as of September 30, 2015. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern.The financial statementsdonot include any adjustments that might be necessary if the Company is unable to continue as a going concern. 

Segment Information

The Company follows the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. As of September 30, 2015 and for the nine months ended September 30, 2015 and 2014, the Company operated in three segments as well as separately identifying the corporate overhead costs. The segments are as follows: Coding – this includes the coding, billing and telecommunications services of the Company; Vascular – this includes all vascular physician practice administration and support services; and Devices – this includes all services related to the medical device and equipment segment.

The Company’s chief financial officer reviews financial information presented on an entity level basis accompanied by disaggregated information about revenues by product type and certain information about geographic regions where appropriate for purposes of making operating decisions and assessing financial performance.

September 30, 2015	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	-	$	306,840	$	626,645	$	-	$	933,485
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		5,285		4,763,586		1,790,906		13,833,063		20,392,840
Depreciation and Amortization		-		95,569		23,843		19,670		139,082
Other (Income) Expense		-		-		3,218		(1,363,915)		(1,360,697)
Assets
Fixed Assets	$	-	$	649,185	$	11,706	$	51,134	$	712,025
Intangible Assets		-		-		34,271		-		34,271

September 30, 2014	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	3,596	$	5,915,419	$	1,508,275	$	-	$	7,427,290
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		3,717		1,111,259		909,647		16,747,739		18,772,362
Depreciation and Amortization		-		969		26,797		23,432		51,198
Other (Income) Expense		-		-		-		1,630,506		1,630,506
Assets
Fixed Assets	$	-	$	57,170	$	16,080	$	39,536	$	112,786
Intangible Assets		-		-		61,687		-		61,687

Generally, any item not related to one of our other segments would be included in the Corporate Column. This includes corporate overhead costs such as consulting fees, legal fees, and other professional fees including all common stock issued for services; and interest expenses, including all fair value measurements of warrants and fair value adjustments related to our derivative liability that have been charged to interest. The Company has determined it would be more appropriate to include a corporate column rather than develop an allocation to our other divisions as the Company has not determined allocation percentages.

Recently Issued Accounting Standards

The Financial Accounting Standards Board and the Securities Exchange commission have issued certain accounting standards updates and regulations that will become effective in subsequent periods. Management does not believe that any of those updates would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect in 2015 and 2014, and it does not believe that any of those pronouncements will have a significant impact on the Company’s consolidated financial statements at the time they become effective.

XML

PREFERRED STOCK - SERIES F AND SERIES G (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Conversion of Stock [Line Items]
Common Stock, Shares, Issued		479,262,001	128,828,942
Common Stock [Member]
Conversion of Stock [Line Items]
Common Stock Capital Shares Reserved For Future Issuance Value		$ 4,000,000
Common Stock, Capital Shares Reserved for Future Issuance		100,000,000
Satisfaction Agreement and Release [Member]
Conversion of Stock [Line Items]
Common Stock Capital Shares Reserved For Future Issuance Value		$ 420,000
Common Stock, Capital Shares Reserved for Future Issuance		10,500,000
Satisfaction Agreement and Release [Member] | Common Stock [Member]
Conversion of Stock [Line Items]
Conversion of Stock, Shares Issued	10,500,000
Conversion Of Stock Weighted Average Term	36 months
Conversion of Stock, Amount Issued	$ 18,000,000
Series F Preferred Stock [Member] | Satisfaction Agreement and Release [Member]
Conversion of Stock [Line Items]
Conversion of Stock, Shares Issued		2,840,000
Conversion of Stock, Shares Converted	2,300,000	700,000
Common Stock Capital Shares Reserved For Future Issuance Value		$ 390,000
Common Stock, Shares, Issued		240,000
Common Stock, Capital Shares Reserved for Future Issuance		2,600,000
Series G Preferred Stock [Member] | Satisfaction Agreement and Release [Member]
Conversion of Stock [Line Items]
Conversion of Stock, Shares Issued		300,000
Conversion of Stock, Shares Converted	4,775	75
Series G Preferred Stock [Member] | Global Settlement Agreements [Member]
Conversion of Stock [Line Items]
Common Stock Capital Shares Reserved For Future Issuance Value		$ 434,833
Common Stock, Capital Shares Reserved for Future Issuance		636
Conversion of Stock, Amount Issued		$ 751,000

XML

NOTES PAYABLE, PREFERRED AND COMMON STOCK, AND WARRANTS (Details Textual)		1 Months Ended																		3 Months Ended			9 Months Ended			12 Months Ended
		Nov. 30, 2015 USD ($) shares	Oct. 31, 2015 USD ($) shares	Jul. 31, 2015 USD ($) shares	Jun. 30, 2015 shares	Jun. 26, 2015 USD ($) $ / shares	May. 31, 2015 USD ($) shares	Mar. 31, 2015 shares	Feb. 28, 2015 USD ($) shares	Jan. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($) $ / shares shares	Nov. 30, 2014 USD ($) shares	Oct. 31, 2014 USD ($) shares	Sep. 30, 2014 USD ($)	Sep. 18, 2014 USD ($) shares	Mar. 31, 2014 USD ($) shares	Feb. 28, 2014 shares	Dec. 31, 2013 USD ($) shares	Jun. 01, 2013 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares shares		Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) $ / shares shares		Sep. 30, 2014 USD ($) shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) shares	Aug. 11, 2015 USD ($)	Apr. 30, 2015 shares	Nov. 10, 2014 USD ($)	Jul. 31, 2014 shares	Jun. 30, 2014 $ / shares	Dec. 31, 2012 USD ($) $ / shares	Jan. 31, 2012 shares	Jun. 30, 2011 shares
Debt Instrument [Line Items]
Notes Payable, Current, Total | $											$ 2,862,836									$ 3,654,564			$ 3,654,564			$ 2,862,836
Preferred Stock, Shares Authorized											15,000,000									15,000,000			15,000,000			15,000,000
Preferred Stock Dividends, Income Statement Impact | $																				$ 0		$ 26,452	$ 0		$ 79,355
Share Price | $ / shares																				$ 0.001			$ 0.001
Common Stock, Shares, Issued											128,828,942									479,262,001			479,262,001			128,828,942
Repayments of Notes Payable | $													$ 450,000										$ 154,000		2,626,420
Debt Instrument, Description																										the Company agreed to pay to the placement agent a fee of 10% of the gross proceeds received by the Company and a warrant equal to 10% of the aggregate number of shares issuable upon conversion of the Notes at an exercise price equal to 110% of the warrant exercise price.
Debt Instrument, Unamortized Discount | $											$ 106,504									$ 36,364			$ 36,364			$ 106,504
Fair Value Assumptions, Expected Volatility Rate																							422.67%
Fair Value Assumptions, Expected Dividend Rate																							0.00%
Common Stock, Shares Authorized											200,000,000									950,000,000			950,000,000			200,000,000
Debt Conversion, Original Debt, Amount | $				$ 200,000
Debt Conversion, Converted Instrument, Amount | $				$ 224,000
Debt Instrument Convertible Number Of Shares				38,711,548									100,000
Share-based Compensation Award, Tranche One [Member]
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount | $						$ 200,000
Share-based Compensation Award, Tranche Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount | $						250,000
Share-based Compensation Award, Tranche Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Repurchased Face Amount | $						$ 50,000
Long-term Debt [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross | $										$ 300,000	$ 350,000															$ 350,000
Debt Instrument, Interest Rate, Stated Percentage									12.00%	12.00%	12.00%															12.00%
Stock Issued During Period, Shares, Share-based Compensation, Gross										300,000	350,000
Percentage Of Warrant Issued											10.00%
Debt Instrument Maturity Period										36 months	36 years
Percentage Of Placement Agent Fees										10.00%	10.00%
Accrued Liabilities | $									$ 14,200		$ 35,000															$ 35,000
Class of Warrant or Right, Outstanding									14,200		35,000															35,000
Notes Payable | $									$ 142,000
Placement Agent Fee Percentage Of Aggregate Purchase Price									10.00%
Percentage Of Warrants Issued									10.00%
Payments for Fees | $										$ 30,000
Interest Expense [Member]
Debt Instrument [Line Items]
Debt Instrument Convertible Number Of Shares													300,000
Promissory Note [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross | $											$ 205,000		$ 250,000													$ 205,000
Debt Instrument, Interest Rate, Stated Percentage											10.00%		10.00%													10.00%
Repayments of Notes Payable | $													$ 40,000
Debt Instrument Maturity Period													30 days
Class of Warrant or Right, Outstanding				607,843
Debt Instrument Convertible Number Of Shares													175,000
Promissory Note Two [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross | $													$ 450,000
Debt Instrument, Interest Rate, Stated Percentage													10.00%
Debt Instrument Maturity Period													60 days
Promissory Note Three [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross | $													$ 40,000
Debt Instrument, Interest Rate, Stated Percentage													10.00%
Short-term Debt | $													$ 250,000
Debt Instrument, Maturity Date, Description													60
Notes Payable [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross | $																														$ 440,000
Debt Instrument, Interest Rate, Stated Percentage																														18.00%
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 1.00															$ 1.00
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross | $																														$ 660,000
Debt Instrument, Interest Rate, Stated Percentage																												0.00%		18.00%
Notes Payable, Current, Total | $																												$ 15,000
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 1.00															$ 1.00
OID Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment | $																				$ 192,500			$ 192,500
Debt Conversion, Converted Instrument, Shares Issued																							218,750,000
Debt Instrument Maturity Period																							12 years
Debt Instrument, Face Amount | $											$ 1,235,218															$ 1,235,218
Debt Instrument, Unamortized Discount | $											$ 185,283									$ 175,000			$ 175,000			$ 185,283
Promissory Note Four [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													103.00%
Short-term Debt | $													$ 100,000
Debt Instrument, Maturity Date, Description													90
Secuirities Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						18.00%
Debt Instrument, Annual Principal Payment | $						$ 560,000
Debt Instrument, Increase, Accrued Interest | $						$ 18
Debt Instrument Maturity Period						12 years
Debt Instrument, Convertible, Conversion Price | $ / shares						$ 0.02
Combined Notes [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount | $				$ 175,790
Debt Conversion, Converted Instrument, Amount | $				$ 350,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Issued								400,000			600,000							300,000		1,000,000	[1]		1,000,000	[1]		600,000	300,000				100,000			100,000	100,000
Preferred Stock, Shares Authorized											1,000,000									1,000,000			1,000,000			1,000,000
Preferred Stock, Conversion Basis	[1]																						N/A
Series E Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Issued											0									0	[2]		0	[2]		0
Preferred Stock, Conversion Basis																			65				65:1	[2]
Preferred Stock, Dividends Per Share, Declared | $ / shares																			$ 0.80
Dividends Payable | $														$ 26,452				$ 25,936				$ 26,452			$ 26,452		$ 25,936
Preferred Stock Dividends, Shares																	2,594		3,384
Dividends, Preferred Stock, Paid-in-kind | $																		$ 25,936	$ 33,843
Conversion of Stock, Shares Issued																			126,280
Dividends, Preferred Stock, Cash | $												$ 75,000
Stock Issued During Period, Shares, Conversion of Convertible Securities												8,596,770
Dividends, Preferred Stock, Stock | $												$ 5,000,000
Series F Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Shares Issued											550,000							550,000		0	[3]		0	[3]		550,000	550,000
Preferred Stock, Shares Authorized											3,000,000							3,000,000		3,000,000			3,000,000			3,000,000	3,000,000
Preferred Stock, Conversion Basis	[3]																						N/A
Proceeds from Issuance of Private Placement | $																$ 1,050,000		$ 1,950,000					$ 3,000,000
Total Stock to be Issued Under Private Offering																1,050,000		1,950,000					3,000,000
Stock to be Issued in Future, Shares Under Private Offerings																		2,450,000
Stock to be Issued in Future, Values Under Private Offerings | $																		$ 1,356,500
Preferred Stock Shares Surrendered During the Period																							700,000
Series F Preferred Stock [Member] | Satisfaction Agreement and Release [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued																							2,840,000
Common Stock, Shares, Issued																				240,000			240,000
Common Stock Shares Value Exchanged for Surrendered of Shares | $																							$ 2,840,000
Series G Preferred Stock [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues																									1,175
Preferred Stock, Shares Issued											0									0	[4]		0	[4]		0
Preferred Stock, Shares Authorized											100,000									100,000			100,000			100,000
Preferred Stock, Conversion Basis	[4]																						N/A
Preferred Stock Dividends, Income Statement Impact | $																$ 1,200
Preferred Stock, Dividend Rate, Percentage																10.00%
Proceeds from Issuance of Private Placement | $											$ 4,920,000												$ 418,000
Total Stock to be Issued Under Private Offering											4,920												418
Stock to be Issued in Future, Values Under Private Offerings | $											$ 1,747,300												$ 397,580
Share Price | $ / shares																																$ 1,000
Series G Preferred Stock [Member] | Promissory Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued											48												173
Series G Preferred Stock [Member] | Promissory Note Two [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																							2,015
Series G Preferred Stock [Member] | Satisfaction Agreement and Release [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued																							300,000
Series F and G Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred Stock, Dividend Rate, Percentage																10.00%
Consulting Services [Member]
Debt Instrument [Line Items]
Stock Issued During Period Shares Issued For Consulting And Other Services																							6,500,000
Minimum [Member]
Debt Instrument [Line Items]
Common Stock, Shares Authorized		950,000,000		350,000,000																950,000,000			950,000,000
Minimum [Member] | OID Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 0.75															$ 0.75
Sale Of Stock Price Per Share Percentage											80.00%
Minimum [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Percentage Of Total Votes								49.00%
Maximum [Member]
Debt Instrument [Line Items]
Common Stock, Shares Authorized		10,950,000,000		950,000,000																10,950,000,000			10,950,000,000
Maximum [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Percentage Of Total Votes							51.00%
Subsequent Event [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues		75,000,000	62,500,000
Debt Instrument, Unamortized Discount | $		$ 60,000	$ 50,000
Subsequent Event [Member] | Series G Preferred Stock [Member] | Promissory Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			23
Common Stock [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues																							2,600,000
Stock Issued During Period, Value, New Issues | $																							$ 390,000
Common Stock, Shares Authorized																													350,000,000
Stock Cancelled During Period Shares																							24,000,000
Warrants To Purchase Common Stock																				30,000,000			30,000,000
Common Stock [Member] | Stock One [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued																							240,000
Common Stock [Member] | Stock Two [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued																							176,100,299
Common Stock [Member] | Stock Three [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued																							56,300,000
Common Stock [Member] | Stock Four [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued																							5,308,376
Common Stock [Member] | Promissory Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued											1,750,000,000												2,000,000,000
Common Stock [Member] | Promissory Note Two [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																							173
Common Stock [Member] | Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments														4,600,000
Common Stock [Member] | Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																							128,764,384
Common Stock [Member] | OID Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 1.00															1.00
Common Stock [Member] | Satisfaction Agreement and Release [Member]
Debt Instrument [Line Items]
Conversion of Stock, Shares Issued					10,500,000
Common Stock [Member] | Maximum [Member] | OID Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 1.00															$ 1.00
Sale Of Stock Price Per Share Percentage											80.00%
Common Stock [Member] | Subsequent Event [Member] | Promissory Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			65,000,000
Common Stock [Member] | Subsequent Event [Member] | Promissory Note Two [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			115,000,000
Warrant [Member]
Debt Instrument [Line Items]
Warrants and Rights Outstanding | $											$ 8,300,000									$ 77,602,436			$ 77,602,436			$ 8,300,000							$ 9,760,000
Consultant Warrants Issued																										1.00	200,000
Fair Value Assumptions, Expected Volatility Rate																							422.67%
Fair Value Assumptions, Expected Dividend Rate																							0.00%
Fair Value Inputs, Discount Rate																							0.95%
Stock Issued During Period, Shares, Share-based Compensation, Forfeited																										312,014
Stock Cancelled During Period Shares																							24,000,000
Warrants To Purchase Common Stock																				30,000,000			30,000,000
Warrant [Member] | Warrant Holder One [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued																										3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 3.00															$ 3.00
Stock Issued During Period, Shares, Share-based Compensation, Forfeited																										2,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											17,688,236															17,688,236
Warrant [Member] | Warrant Holder Two [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 1.00															$ 1.00
Stock Issued During Period, Shares, Share-based Compensation, Forfeited																										2,500,000
Warrant [Member] | Warrant Holder Three [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Forfeited																										3,300,000
Warrant [Member] | Executive Officer [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 0.25															$ 0.25
Class of Warrant or Right, Outstanding											12,000,000															12,000,000
Warrant [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued																							14,200
Warrant [Member] | Convertible Note Holders [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 1.00															$ 1.00
Warrants Issued To Purchase Of Common Stock Shares											823,530															823,530
Warrant [Member] | Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 1.00															$ 1.00							$ 1.00
Warrant [Member] | Maximum [Member] | Warrant Holder One [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 1.00															$ 1.00
Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							10.00%		10.00%
Debt Instrument Maturity Period									36 months
Notes Payable | $							$ 160,000		$ 170,000
Promissory Notes Original Issue Discounts [Member]
Debt Instrument [Line Items]
Warrants Issued											164,706															164,706
Debt Conversion, Converted Instrument, Warrants or Options Issued											164,706
Payments for Fees | $											$ 104,935
Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage										0.00%
Repayments of Debt | $							$ 90,000
Short-term Debt | $															$ 200,000
Debt Conversion, Converted Instrument, Shares Issued							5,000,000								20,000
Notes Payable | $										$ 220,000
Debt Conversion, Original Debt, Amount | $							$ 350,000
Debt Conversion, Converted Instrument, Amount | $							$ 260,000
Promissory Note [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					22,000,000

[1] Issued 100,000 shares to the principal owners of Millennium Healthcare Solutions Inc. upon acquisition of the net assets of that company; and issued 900,000 to the officers of Millennium Healthcare Inc.

[2] Issued to an unrelated third party in conversion of the Series D Preferred Stock. Settlement and conversion completed with all shareholders. There are no shares issued and outstanding as of September 30, 2015.

[3] Issued to investors as part of a private offering. There are no shares issued and outstanding as of September 30, 2015.

[4] Issued to investors as part of a private offering and to former note holders as note settlements and satisfaction. There are no shares issued and outstanding as of September 30, 2015.

XML

PREFERRED STOCK - SERIES F AND SERIES G

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Preferred Stock [Text Block]

NOTE 2- PREFERRED STOCK - SERIES F AND SERIES G

During 2015, the Company entered into Satisfaction Agreements and Releases with various Series F holders in which 700,000 shares of Series F preferred stock were surrendered and exchanged for 2,840,000 shares of the Company’s common stock. Further, 240,000 of these common shares were issued and 2,600,000 shares valued at $390,000 were recorded as a liability for common stock to be issued.

During 2015, the Company entered into a Satisfaction Agreement and Release with a Series G holder in which 75 shares of Series G preferred stock were surrendered and exchanged for 300,000 shares of the Company’s common stock.

In June 2015, the Company entered into a unified Satisfaction Agreement and Release with various Series F and Series G holders in which 2,300,000 shares of Series F preferred stock and 4,775 shares of Series G preferred stock were surrendered and exchanged for shares of the Company’s common stock. The terms of the Agreement call for a 10,500,000 block of common shares at settlement and for common stock “true-up” blocks issuable under certain terms over 36 months until the common stock issued has reached a total realized cash value of $18,000,000. As a result, 10,500,000 shares of common stock for the initial block were valued at $420,000 and recorded as a liability for stock to be issued and 100,000,000 shares of common stock in reserve were valued at $4,000,000 and also recorded as a liability for stock to be issued.

In September 2015, the Company entered into Global Settlement Agreements with various promissory note holders in which $751,000 in the aggregate of remaining outstanding note balances were settled and satisfied for shares of the Company’s common and Series G preferred stock. As a result, 636 shares of Series G preferred stock were valued at $434,833 and recorded as a liability for stock to be issued.

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2015		Dec. 31, 2014
Allowance for Doubtful Accounts Receivable	$ 8,450,000		$ 3,000,000
Notes payable debt discounts (in dollars)	0		220,878
Debt instrument, unamortized discount (in dollars)	$ 36,364		$ 106,504
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	15,000,000		15,000,000
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Common stock, shares authorized	950,000,000		200,000,000
Common stock, shares issued	479,262,001		128,828,942
Common stock, shares outstanding	479,262,001		128,828,942
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	[1]	$ 0.0001
Preferred stock, shares authorized	1,000,000		1,000,000
Preferred stock, shares issued	1,000,000	[1]	600,000
Preferred stock, shares outstanding	1,000,000		600,000
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	[2]	$ 0.0001
Preferred stock, shares issued	0	[2]	0
Preferred stock, shares outstanding	0		0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	[3]	$ 0.0001
Preferred stock, shares issued	0	[3]	0
Preferred stock, shares outstanding	0		0
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	[4]	$ 0.0001
Preferred stock, shares issued	0	[4]	0
Preferred stock, shares outstanding	0		0
Series F Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	[5]	$ 0.0001
Preferred stock, shares authorized	3,000,000		3,000,000
Preferred stock, shares issued	0	[5]	550,000
Preferred stock, shares outstanding	0		550,000
Series G Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	[6]	$ 0.0001
Preferred stock, shares authorized	100,000		100,000
Preferred stock, shares issued	0	[6]	0
Preferred stock, shares outstanding	0		0

[1] Issued 100,000 shares to the principal owners of Millennium Healthcare Solutions Inc. upon acquisition of the net assets of that company; and issued 900,000 to the officers of Millennium Healthcare Inc.

[2] Issued to an unrelated third party in conversion of the Line of Credit. There are no shares issued and outstanding as of September 30, 2015.

[3] Issued to an unrelated third party in conversion of the Series B Preferred Stock and additional funds provided. There are no shares issued and outstanding as of September 30, 2015.

[4] Issued to an unrelated third party in conversion of the Series D Preferred Stock. Settlement and conversion completed with all shareholders. There are no shares issued and outstanding as of September 30, 2015.

[5] Issued to investors as part of a private offering. There are no shares issued and outstanding as of September 30, 2015.

[6] Issued to investors as part of a private offering and to former note holders as note settlements and satisfaction. There are no shares issued and outstanding as of September 30, 2015.

XML

NOTES PAYABLE, PREFERRED AND COMMON STOCK, AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Schedule of Stock by Class [Table Text Block]

The Company has amended their certificates of designation to authorize the issuance of 6 separate series of preferred stock.

September 30, 2015

							Conversion
			Number				to
Preferred	Authorized	Issue	of Shares		Par		Common
Stock	Date	Date	Issued/Outstanding		Value		Stock
Series “A" (1)	June 14, 2011	June 2011		1,000,000	$	.0001	N/A
Series “B" (2)	October 2011	October 2011		0	$	.0001	1.50:1
Series “D” (3)	March 30, 2012	April 2012		0	$	.0001	30:1
Series “E” (4)	June 1, 2013	June 2013		0	$	.0001	65:1
Series “F” (5)	December 2, 2013	December 2013		0	$	.0001	N/A
Series “G” (6)	March 7, 2014	March 2014		0	$	.0001	N/A

(1) Issued 100,000 shares to the principal owners of Millennium Healthcare Solutions Inc. upon acquisition of the net assets of that company; and issued 900,000 to the officers of Millennium Healthcare Inc. 

(2) Issued to an unrelated third party in conversion of the Line of Credit. There are no shares issued and outstanding as of September 30, 2015.

(3) Issued to an unrelated third party in conversion of the Series B Preferred Stock and additional funds provided. There are no shares issued and outstanding as of September 30, 2015.

(4) Issued to an unrelated third party in conversion of the Series D Preferred Stock. Settlement and conversion completed with all shareholders. There are no shares issued and outstanding as of September 30, 2015.

(5) Issued to investors as part of a private offering. There are no shares issued and outstanding as of September 30, 2015.

(6) Issued to investors as part of a private offering and to former note holders as note settlements and satisfaction. There are no shares issued and outstanding as of September 30, 2015.  

XML

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 10, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	true
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Entity Registrant Name	MILLENNIUM HEALTHCARE INC.
Entity Central Index Key	0001582054
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MHCC
Entity Common Stock, Shares Outstanding		664,512,001
Amendment Description	The purpose of this Amendment No. 1 to Millennium Healthcare Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, filed with the Securities and Exchange Commission on November 23, 2015 (the “Form 10-Q”), is solely to describe the partial assignment, amendment and further settlement of a promissory note held by an individual. This filing does not modify the original Form 10-Q except as specifically noted herein. No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

XML

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

                                  The reconciliation of income tax benefit at the U.S. statutory rate of 34% for the nine months ended September 30, 2015 and 2014 to the Company’s effective tax rate is as follows:

 

	Nine Months Ended
	September 30,			September 30,
	2015			2014
U.S. federal statutory rate		-34.0	%		-34.0	%
State income tax, net of federal benefit		-6.0	%		-6.0	%
Permanent differences		-0.8	%		-0.8	%
Change in valuation allowance		40.8	%		40.8	%
Income Tax provision (benefit)		0.0	%		0.0	%

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The benefit for income tax is summarized as follows:

	Nine Months Ended
	September 30,		September 30,
	2015		2014
Federal:
Current	$	-	$	-
Deferred		(6,260,000)		(4,561,000)
State:
Current
Deferred		(1,079,000)		(786,000)
Change in valuation allowance		7,339,000		5,347,000
Income Tax provision (benefit)	$	-	$	-

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
REVENUE	$ 149,935	$ 6,366,728	$ 933,485	$ 7,427,290
OPERATING EXPENSES
Payroll, consulting and professional fees	980,745	8,947,853	13,304,426	16,768,150
Rent	272,993	268,617	743,622	450,723
General and administrative	235,716	365,714	889,677	1,003,489
Depreciation and amortization	46,468	17,596	139,082	51,198
Cost of Devices	0	550,000	0	550,000
Bad debt expense	0	0	5,455,115	0
Total operating expenses	1,535,922	10,149,780	20,531,922	18,823,560
NET LOSS BEFORE OTHER INCOME (EXPENSE) AND PREFERRED STOCK DIVIDENDS	(1,385,987)	(3,783,052)	(19,598,437)	(11,396,270)
OTHER INCOME (EXPENSE)
Interest expense	(280,795)	(382,938)	(2,727,498)	(848,218)
Gain (loss) on change in fair value of derivative liability	36,210	345,496	4,088,195	(782,288)
Total other income (expense)	(244,585)	(37,442)	1,360,697	(1,630,506)
NET (LOSS) BEFORE PREFERRED STOCK DIVIDNEDS	(1,630,572)	(3,820,494)	(18,237,740)	(13,026,776)
Preferred stock dividends	0	(26,452)	0	(79,355)
NET (LOSS)	$ (1,630,572)	$ (3,846,946)	$ (18,237,740)	$ (13,106,131)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC & DILUTED (in shares)	376,616,131	82,091,238	233,911,019	77,330,185
NET (LOSS) PER SHARE - BASIC & DILUTED (in dollars per share)	$ (0.00)	$ (0.05)	$ (0.08)	$ (0.17)

XML

CREDIT RISK AND OTHER CONCENTRATIONS

9 Months Ended

Sep. 30, 2015

Risks and Uncertainties [Abstract]

Concentration Risk Disclosure [Text Block]

NOTE 7- CREDIT RISK AND OTHER CONCENTRATIONS

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables. The Company places its cash with high credit quality financial institutions. At times, such cash and cash equivalents may exceed the FDIC insured limit of $250,000.

Accounts receivable, net of allowance, from two customers were $4,775,507, which accounted for approximately 92% of the total receivables at December 31, 2014.

Revenue from one customer was $76,140 and from another was $450,000, which accounted for approximately 8% and 48% of the total revenues respectively for the nine months ended September 30, 2015 and revenue from one customer was $1,350,000 and from another was $5,775,312, which accounted for approximately 18% and 78% of the total revenues, respectively for the nine months ended September 30, 2014.

XML

COMMITMENTS

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments Disclosure [Text Block]

NOTE 6- COMMITMENTS

In April 2014, the Company entered into a five year two month lease agreement in New York City, New York for executive offices of the Company, which requires an annual payment of approximately $283,000 for the first year and increases 3% per year subsequent thereto plus any increases in real estate taxes over the base year, as defined. The Company paid a security deposit of $259,402.

In April 2014, the Company entered into a five year lease agreement in Boynton Beach, Florida for the development of a new 30,000 square foot facility. The lease provides for first year rent of approximately $103,000 plus operating expenses of approximately $98,000 plus annual increases. The Company paid a security deposit of $36,099.

In March 2015, the Company vacated its Boynton Beach, Florida warehouse and storage facility and entered into a month to month operating agreement and provides for the following logistics and warehousing fees: $15 per incoming new pallet handling, $17 per pallet monthly storage and $1.67 logistics fee per unit sold. The Company is responsible for all shipping costs.

In June 2015, the Company has also vacated its Garden City, New York offices and has relocated to Melville, New York.

The Company no longer occupies any leased space. The Company is currently engaged in legal proceedings with former landlords regarding certain leased space the Company had previously occupied. The Company is currently in ongoing negotiations to settle such legal actions.

While obligated under certain non-cancelable operating leases, rental expense was accounted for on the straight-line method, in which the excess of recognized rent expense over scheduled lease payments was included in accounts payable and accrued expenses.

Rental expense charged to operations aggregated $743,622 and $450,723 for the nine months ended September 30, 2015 and 2014, respectively.

In July 2015, the Company entered into an asset purchase agreement with HealthPath, LLC and its WellPath System, which is a Health Information Exchange (HIE) system that can electronically move clinical information among different healthcare information systems while maintaining the meaning of the information being exchanged. Further in July 2015, the Company also entered a letter of intent to acquire the MedX Group, a Healthcare Information Technology (HIT) company, which offers an integrated suite of products that allow healthcare providers to share information across healthcare ecosystems.

Employment Agreements

The Company has entered into employment agreements and has amended employment agreements with additional and existing key management individuals in 2014. The Company has issued stock bonuses which vest over a one to three-year period to certain individuals. The unvested portion is reflected as deferred compensation, with the vested portion expensed as stock based compensation.

In January 2015 the Company entered into an employment agreement with a key management individual. The Company is to issue a stock bonus which vests over a three-year period. The unvested portion will be reflected as deferred compensation, with the vested portion expensed as stock based compensation. The individual is no longer employed by the Company and any deferred compensation has been fully amortized.

In June 2015 the Company entered into an employment agreement with a key management individual. As a result of this agreement, the Company is to issue equity compensation to that individual. The unvested portion will be reflected as deferred compensation, with the vested portion expensed as stock based compensation over a five-year period. The individual is no longer employed by the Company and any deferred compensation has been fully amortized.

In June 2015 the Company entered into an employment agreement with a key management individual. As a result of this agreement, the Company is to issue equity compensation to that individual. The unvested portion will be reflected as deferred compensation, with the vested portion expensed as stock based compensation over a five-year period.

In August 2015 the Company entered into an employment agreement with a key management individual. As a result of this agreement, the Company is to issue common stock options to that individual. The unvested portions will be reflected as deferred compensation, with the vested portions expensed as stock based compensation over a six-month and one-year period. The individual is no longer employed by the Company and any deferred compensation has been fully amortized.

XML

NOTES PAYABLE, PREFERRED AND COMMON STOCK, AND WARRANTS (Details) - $ / shares		1 Months Ended	9 Months Ended
		Jun. 01, 2013	Sep. 30, 2015		Mar. 31, 2015	Dec. 31, 2014	Jul. 31, 2014	Dec. 31, 2013	Jan. 31, 2012	Jun. 30, 2011
Class of Stock [Line Items]
Preferred Stock, Par Value			$ 0.0001			$ 0.0001
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Authorized Date	[1]		Jun. 14, 2011
Preferred Stock, Issue Date	[1]		June 2011
Preferred Stock, Number of Shares			1,000,000	[1]	400,000	600,000	100,000	300,000	100,000	100,000
Preferred Stock, Par Value			$ 0.0001	[1]		$ 0.0001
Preferred Stock, Conversion to Common Stock	[1]		N/A
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Authorized Date	[2]		Oct. 31, 2011
Preferred Stock, Issue Date	[2]		October 2011
Preferred Stock, Number of Shares			0	[2]		0
Preferred Stock, Par Value			$ 0.0001	[2]		$ 0.0001
Preferred Stock, Conversion to Common Stock	[2]		1.50:1
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Authorized Date	[3]		Mar. 30, 2012
Preferred Stock, Issue Date	[3]		April 2012
Preferred Stock, Number of Shares			0	[3]		0
Preferred Stock, Par Value			$ 0.0001	[3]		$ 0.0001
Preferred Stock, Conversion to Common Stock	[3]		30:1
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Authorized Date	[4]		Jun. 01, 2013
Preferred Stock, Issue Date	[4]		June 2013
Preferred Stock, Number of Shares			0	[4]		0
Preferred Stock, Par Value			$ 0.0001	[4]		$ 0.0001
Preferred Stock, Conversion to Common Stock		65	65:1	[4]
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Authorized Date	[5]		Dec. 02, 2013
Preferred Stock, Issue Date	[5]		December 2013
Preferred Stock, Number of Shares			0	[5]		550,000		550,000
Preferred Stock, Par Value			$ 0.0001	[5]		$ 0.0001
Preferred Stock, Conversion to Common Stock	[5]		N/A
Series G Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Authorized Date	[6]		Mar. 07, 2014
Preferred Stock, Issue Date	[6]		March 2014
Preferred Stock, Number of Shares			0	[6]		0
Preferred Stock, Par Value			$ 0.0001	[6]		$ 0.0001
Preferred Stock, Conversion to Common Stock	[6]		N/A

[1] Issued 100,000 shares to the principal owners of Millennium Healthcare Solutions Inc. upon acquisition of the net assets of that company; and issued 900,000 to the officers of Millennium Healthcare Inc.

[2] Issued to an unrelated third party in conversion of the Line of Credit. There are no shares issued and outstanding as of September 30, 2015.

[3] Issued to an unrelated third party in conversion of the Series B Preferred Stock and additional funds provided. There are no shares issued and outstanding as of September 30, 2015.

[4] Issued to an unrelated third party in conversion of the Series D Preferred Stock. Settlement and conversion completed with all shareholders. There are no shares issued and outstanding as of September 30, 2015.

[5] Issued to investors as part of a private offering. There are no shares issued and outstanding as of September 30, 2015.

[6] Issued to investors as part of a private offering and to former note holders as note settlements and satisfaction. There are no shares issued and outstanding as of September 30, 2015.

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The following table represents the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2015:

	Level 1		Level 2		Level 3		Total
Cash	$	21,975	$	-	$	-	$	21,975
Total assets	$	21,975	$	-	$	-	$	21,975
Notes payable, net of debt discount and OID	$	-	$	-	$	3,796,564	$	3,796,564
Embedded conversion feature and derivative liability	$	-	$	-	$	4,023	$	4,023
Total liabilities	$	-	$	-	$	3,800,587	$	3,800,587

The following table represents the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2014:

	Level 1		Level 2		Level 3		Total
Cash	$	177,974	$	-	$	-	$	177,974
Total assets	$	177,974	$	-	$	-	$	177,974
Notes payable, net of debt discount and OID	$	-	$	-	$	1,515,444	$	1,515,444
Embedded conversion feature and derivative liability	$	-	$	-	$	3,045,185	$	3,045,185
Total liabilities	$	-	$	-	$	4,560,629	$	4,560,629

	For the Nine Months		For the Nine
	Ended		Months Ended
	2015		2014
Total gain/(loss) from revaluation of derivatives included in earnings:	$	4,088,195	$	(782,288)

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following tables provide reconciliations of beginning and ending balances at September 30, 2015:  

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Notes		Embedded conversion feature
	Payable		and derivative liability		Total
September 30, 2015
Beginning balance		3,212,836		1,061,476		4,274,312
Transfers into Level 3		-		-		-
Transfers out of Level 3		-		-		-
Total gains or losses		-		-		-
included in earnings (or changes in net assets)		-		(4,088,195)		(4,088,195)
included in other comprehensive income		-		-		-
Purchases, issuances, sales, and settlements		-		-		-
Purchases		-		-		-
Issuances		1,945,805		-		1,945,805
Sales		-		-		-
Settlements		(1,362,077)		3,030,742		1,668,665
Ending balance		3,796,564		4,023		3,800,587

XML

BASIS OF PRESENTATION AND BUSINESS DESCRIPTION (Policies)

9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Liquidity Disclosure, Policy [Policy Text Block]

Going Concern

These consolidated financial statements are presented on the basis that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred operating losses for the past several years, has a working capital deficiency of $16,499,245 and a stockholders’ deficit of $15,854,370 as of September 30, 2015. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern.The financial statementsdonot include any adjustments that might be necessary if the Company is unable to continue as a going concern. 

Segment Reporting, Policy [Policy Text Block]

Segment Information

The Company follows the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. As of September 30, 2015 and for the nine months ended September 30, 2015 and 2014, the Company operated in three segments as well as separately identifying the corporate overhead costs. The segments are as follows: Coding – this includes the coding, billing and telecommunications services of the Company; Vascular – this includes all vascular physician practice administration and support services; and Devices – this includes all services related to the medical device and equipment segment.

The Company’s chief financial officer reviews financial information presented on an entity level basis accompanied by disaggregated information about revenues by product type and certain information about geographic regions where appropriate for purposes of making operating decisions and assessing financial performance.

September 30, 2015	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	-	$	306,840	$	626,645	$	-	$	933,485
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		5,285		4,763,586		1,790,906		13,833,063		20,392,840
Depreciation and Amortization		-		95,569		23,843		19,670		139,082
Other (Income) Expense		-		-		3,218		(1,363,915)		(1,360,697)
Assets
Fixed Assets	$	-	$	649,185	$	11,706	$	51,134	$	712,025
Intangible Assets		-		-		34,271		-		34,271

September 30, 2014	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	3,596	$	5,915,419	$	1,508,275	$	-	$	7,427,290
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		3,717		1,111,259		909,647		16,747,739		18,772,362
Depreciation and Amortization		-		969		26,797		23,432		51,198
Other (Income) Expense		-		-		-		1,630,506		1,630,506
Assets
Fixed Assets	$	-	$	57,170	$	16,080	$	39,536	$	112,786
Intangible Assets		-		-		61,687		-		61,687

Generally, any item not related to one of our other segments would be included in the Corporate Column. This includes corporate overhead costs such as consulting fees, legal fees, and other professional fees including all common stock issued for services; and interest expenses, including all fair value measurements of warrants and fair value adjustments related to our derivative liability that have been charged to interest. The Company has determined it would be more appropriate to include a corporate column rather than develop an allocation to our other divisions as the Company has not determined allocation percentages.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

The Financial Accounting Standards Board and the Securities Exchange commission have issued certain accounting standards updates and regulations that will become effective in subsequent periods. Management does not believe that any of those updates would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect in 2015 and 2014, and it does not believe that any of those pronouncements will have a significant impact on the Company’s consolidated financial statements at the time they become effective.

XML

CONTINGENCIES

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Contingencies Disclosure [Text Block]

NOTE 8- CONTINGENCIES

On August 11, 2014, as previously disclosed, LMARK Holding LLC (“LMARK”) and Cypress Drive Partners LLC (“Cypress”) (“Cypress and LMARK are collectively referred to as the “Members”) filed a summons’s and complaint in the United States District Court Eastern District of New York against the Company (the “Federal Action”). The complaint (among other allegations) alleges that the Members sought to convert their respective Series E Preferred Shares and the Company refused to honor their requests. The complaint asks that the court order the Company to issue 1,950,000 unrestricted shares of its common stock to the Members. The Complaint asserts claims for breach of contract and alleges that the Members were injured in an amount to be determined at trial but not less than $1,000,000. The Company denies these allegations.

On November 13, 2014, the Company, Cypress and LMARK entered into a Settlement Agreement. Pursuant to the Settlement Agreement, on or before November 20, 2014, the Company shall issue: 812,500 shares of unrestricted common stock to Cypress in full conversion of their 12,500 Series E Preferred Shares, (ii) 1,137,500 unrestricted shares of common stock to LMARK in full conversion of their 17,500 Series E Preferred Shares, (iii) 416,000 restricted shares of common stock to LMARK and (iv) 584,000 restricted shares of common stock to Cypress. The parties agreed to promptly file a Stipulation of Voluntary Dismissal with Prejudice of the Federal Action. The Company received a release (subject to the terms of the Settlement Agreement) from Cypress and LMARK including with respect to the claims in the Federal Action and the Company gave Cypress and LMARK a release (subject to the terms of the Settlement Agreement).

On August 12, 2014, as previously disclosed, Aquafina Design LLC whose purported members are Cypress and LMARK, filed a summons and complaint with the Supreme Court of the State of New York, county of Nassau (the “Aquafina Action”) asserting that it provided the Company with certain loans, and was issued (among other securities) 110,000 detachable warrants, with each warrant giving it the right to purchase 30 common shares, for a total of 3,300,000 common shares.  The complaint further asserts that Aquafina exercised all of its warrants on a cashless basis on March 5, 2014 and was entitled to receive 1,312,048 unrestricted common shares and that the Company has not issued such shares.  The complaint seeks compensatory damages for breach of contract in favor of Aquafina in an amount to be determined at trial, but not less than $1,088,990.  The Company denies these allegations.

On November 13, 2014, the Company and Aquafina entered into a Settlement Agreement. Pursuant to the Settlement Agreement, the Company agreed to issue 2,000,000 restricted shares of common stock on or before November 20, 2014, in full satisfaction of any and all issues set forth in the Settlement Agreement, including but not limited to any claims for cashless warrants or a preferred offering. The Company also received a release from Aquafina pursuant to which Aquafina released all claims set forth in the Aquafina Action (subject to the terms of the Settlement Agreement) and the parties agreed to promptly file a Stipulation of Discontinuance with Prejudice of the Aquafina Action. Pursuant to the Settlement Agreement the Company also gave Aquafina a release (subject to the terms of the Settlement Agreement).

The Company is currently engaged in several ongoing legal proceedings with certain landlords in New York, New Jersey and Florida regarding certain leased space the Company had previously occupied. The Company has made the decision to move to a virtual model for its Florida inventory warehousing and fulfillment, and has relocated its New York corporate offices. The company is currently in ongoing negotiations to settle such legal actions.

The Company is currently in ongoing litigation to settle certain claims regarding compensation with one of its suppliers. The Company is currently in ongoing negotiations to settle such legal actions.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 9- SUBSEQUENT EVENTS

Common Stock

See Note 3 relating to the increase in the number of authorized shares of common stock of the Company, par value $0.0001 per share from 950,000,000 shares to 10,950,000,000 shares.

Promissory Notes – Original Issue Discount

During October 2015, the Company issued an original issue discount note (“OID Note”) with an entity for a principal amount of $55,000 along with 62,500,000 shares of the Company’s common stock. The OID Note matures in 12 months and was issued at an original issue discount of $50,000.  No regularly scheduled interest payments shall be made on the OID Notes.

During November 2015, the Company issued an original issue discount note (“OID Note”) with an entity for a principal amount of $66,000 along with 75,000,000 shares of the Company’s common stock. The OID Note matures in 12 months and was issued at an original issue discount of $60,000.  No regularly scheduled interest payments shall be made on the OID Notes.

Contingencies

In October 2015, a summons and notice of motion for summary judgement in lieu of complaint in the Supreme Court of the State of New York, County of New York was filed against the Company (the “Motion”). The Motion (among other allegations) requests an order granting the Plaintiffs summary judgements under various alleged notes aggregating $1,007,482 plus all additional accruing interest and costs of collection. The Motion asserts claims and alleges that the Company is in default under various promissory notes held by the Plaintiffs. The Company denies these allegations.

In October 2015, the Company received a notice of default from a holder of certain promissory notes. The notice demanded the timely satisfaction of a required quarterly interest payment under the terms of the notes. The Company is addressing the default, and is currently in negotiations with the holder and a third party to have the note purchased and assigned.

XML

BASIS OF PRESENTATION AND BUSINESS DESCRIPTION (Tables)

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The Company’s chief financial officer reviews financial information presented on an entity level basis accompanied by disaggregated information about revenues by product type and certain information about geographic regions where appropriate for purposes of making operating decisions and assessing financial performance.

September 30, 2015	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	-	$	306,840	$	626,645	$	-	$	933,485
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		5,285		4,763,586		1,790,906		13,833,063		20,392,840
Depreciation and Amortization		-		95,569		23,843		19,670		139,082
Other (Income) Expense		-		-		3,218		(1,363,915)		(1,360,697)
Assets
Fixed Assets	$	-	$	649,185	$	11,706	$	51,134	$	712,025
Intangible Assets		-		-		34,271		-		34,271

September 30, 2014	Coding		Device		Vascular		Corporate		Total
Segmented Operating Revenues	$	3,596	$	5,915,419	$	1,508,275	$	-	$	7,427,290
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense		3,717		1,111,259		909,647		16,747,739		18,772,362
Depreciation and Amortization		-		969		26,797		23,432		51,198
Other (Income) Expense		-		-		-		1,630,506		1,630,506
Assets
Fixed Assets	$	-	$	57,170	$	16,080	$	39,536	$	112,786
Intangible Assets		-		-		61,687		-		61,687

XML

SUBSEQUENT EVENTS (Details Textual) - USD ($)	1 Months Ended
	Nov. 30, 2015	Oct. 31, 2015	Sep. 30, 2015	Jul. 31, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.0001		$ 0.0001
Common Stock, Shares Authorized			950,000,000		200,000,000
Debt Instrument, Unamortized Discount			$ 36,364		$ 106,504
Maximum [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized	10,950,000,000		10,950,000,000	950,000,000
Minimum [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized	950,000,000		950,000,000	350,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	75,000,000	62,500,000
Debt Instrument, Term	12 months	12 months
Debt Instrument, Unamortized Discount	$ 60,000	$ 50,000
Loss Contingency, Allegations		The Motion (among other allegations) requests an order granting the Plaintiffs summary judgements under various alleged notes aggregating $1,007,482 plus all additional accruing interest and costs of collection.
Subsequent Event [Member] | Original Issue Discount Note [Member]
Subsequent Event [Line Items]
Notes Payable	$ 66,000	$ 55,000

XML

BASIS OF PRESENTATION AND BUSINESS DESCRIPTION (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
ORGANIZATION AND BUSINESS DESCRIPTION [Line Items]
Increase (Decrease) in Operating Capital, Total	$ 16,499,245
Stockholders' Deficit	$ 15,854,370	$ 2,390,368

XML

INCOME TAXES (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Federal:
Current	$ 0	$ 0
Deferred	$ (6,260,000)	$ (4,561,000)
State:
Current
Deferred	$ (1,079,000)	$ (786,000)
Change in valuation allowance	7,339,000	5,347,000
Income Tax provision (benefit)	$ 0	$ 0

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)	$ (18,237,740)	$ (13,106,131)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	139,081	51,198
Non-cash interest	150,000	137,153
(Gain) loss on change in fair value of derivative	(4,088,195)	782,288
Preferred stock dividend	0	79,355
Amortization of deferred compensation	4,263,489	984,212
Share based compensation	8,856,806	11,058,959
Provisions for doubtful accounts	5,455,115	0
Change in operating assets and liabilities
Prepaid expenses	549,481	(498,257)
Accounts receivable	(664,518)	(6,863,015)
Inventory	0	(77,638)
Accounts payable and accrued expenses	1,244,306	142,033
Total adjustments	15,905,564	5,796,805
Net cash used in operating activities	(2,332,176)	(7,309,326)
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposits	(2,429)	(296,332)
Acquisition of fixed assets	(40,595)	(58,139)
Disposition of fixed assets	0	13,378
Net cash used in investing activities	(43,024)	(341,093)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of preferred and common stock for cash (including liability for shares to be issued)	1,014,950	8,445,950
Proceeds received from notes payable	1,423,500	1,893,218
Repayments of notes payable	(154,000)	(2,626,420)
Net cash provided by financing activities	2,284,450	7,712,748
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(90,750)	62,329
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	112,725	115,645
CASH AND CASH EQUIVALENTS - END OF PERIOD	21,975	177,974
Cash paid during the period for:
Interest	0	168,883
Taxes	0	0
NON-CASH SUPPLEMENTAL INFORMATION:
Issuance of common stock for liability of stock to be issued	5,667,409	4,105,550
Issuance (cancellation) of preferred stock for liability of stock to be issued, net	(2,662,120)	2,269,500
Derivative liability issued for debt discount	0	233,321
Deferred compensation paid through issuance of common stock and liability to issue common stock	$ 0	$ 2,643,000

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 5- FAIR VALUE MEASUREMENTS

The Company adopted certain provisions of ASC Topic 820. ASC 820 defines fair value, provides a consistent framework for measuring fair value under generally accepted accounting principles and expands fair value financial statement disclosure requirements. ASC 820’s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820 classifies these inputs into the following hierarchy:

Level 1 inputs: Quoted prices for identical instruments in active markets.

Level 2 inputs: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 inputs: Instruments with primarily unobservable value drivers.

The following table represents the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2015:

	Level 1		Level 2		Level 3		Total
Cash	$	21,975	$	-	$	-	$	21,975
Total assets	$	21,975	$	-	$	-	$	21,975
Notes payable, net of debt discount and OID	$	-	$	-	$	3,796,564	$	3,796,564
Embedded conversion feature and derivative liability	$	-	$	-	$	4,023	$	4,023
Total liabilities	$	-	$	-	$	3,800,587	$	3,800,587

The following table represents the fair value hierarchy for those financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2014:

	Level 1		Level 2		Level 3		Total
Cash	$	177,974	$	-	$	-	$	177,974
Total assets	$	177,974	$	-	$	-	$	177,974
Notes payable, net of debt discount and OID	$	-	$	-	$	1,515,444	$	1,515,444
Embedded conversion feature and derivative liability	$	-	$	-	$	3,045,185	$	3,045,185
Total liabilities	$	-	$	-	$	4,560,629	$	4,560,629

	For the Nine Months		For the Nine
	Ended		Months Ended
	2015		2014
Total gain/(loss) from revaluation of derivatives included in earnings:	$	4,088,195	$	(782,288)

The carrying amounts of our short and long term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

We calculated the fair value of the embedded conversion feature and derivative liability using the Black-Scholes option-pricing model with the following assumptions: Fair value of stock $0.001; exercise price $0.10 to $1.00; risk free interest rate 0.95%, term of 5 years; volatility rate of 422.67%; dividend yield of 0%.

The following tables provide reconciliations of beginning and ending balances at September 30, 2015:  

	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Notes		Embedded conversion feature
	Payable		and derivative liability		Total
September 30, 2015
Beginning balance		3,212,836		1,061,476		4,274,312
Transfers into Level 3		-		-		-
Transfers out of Level 3		-		-		-
Total gains or losses		-		-		-
included in earnings (or changes in net assets)		-		(4,088,195)		(4,088,195)
included in other comprehensive income		-		-		-
Purchases, issuances, sales, and settlements		-		-		-
Purchases		-		-		-
Issuances		1,945,805		-		1,945,805
Sales		-		-		-
Settlements		(1,362,077)		3,030,742		1,668,665
Ending balance		3,796,564		4,023		3,800,587

XML

INCOME TAXES (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Taxes [Line Items]
Operating Loss Carry forwards Expiration Period	2030
Operating Loss Carryforwards, Limitations on Use	Utilization of the NOLs may be subject to limitation under the Internal Revenue Code Section 382 should there be a greater than 50% ownership changeas determined under regulations.
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	(34.00%)	(34.00%)
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 67,000,000

XML

BASIS OF PRESENTATION AND BUSINESS DESCRIPTION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Segmented Operating Revenues	$ 149,935	$ 6,366,728	$ 933,485	$ 7,427,290
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense			20,392,840	18,772,362
Depreciation and Amortization	46,468	17,596	139,082	51,198
Other (Income) Expense			(1,360,697)	1,630,506
Segmented Fixed Assets
Fixed Assets	712,025	112,786	712,025	112,786	$ 789,950
Intangible Assets	34,271	61,687	34,271	61,687
Coding [Member]
Segment Reporting Information [Line Items]
Segmented Operating Revenues			0	3,596
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense			5,285	3,717
Depreciation and Amortization			0	0
Other (Income) Expense			0	0
Segmented Fixed Assets
Fixed Assets	0	0	0	0
Intangible Assets	0	0	0	0
Device [Member]
Segment Reporting Information [Line Items]
Segmented Operating Revenues			306,840	5,915,419
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense			4,763,586	1,111,259
Depreciation and Amortization			95,569	969
Other (Income) Expense			0	0
Segmented Fixed Assets
Fixed Assets	649,185	57,170	649,185	57,170
Intangible Assets	0	0	0	0
Vascular [Member]
Segment Reporting Information [Line Items]
Segmented Operating Revenues			626,645	1,508,275
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense			1,790,906	909,647
Depreciation and Amortization			23,843	26,797
Other (Income) Expense			3,218	0
Segmented Fixed Assets
Fixed Assets	11,706	16,080	11,706	16,080
Intangible Assets	34,271	61,687	34,271	61,687
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Segmented Operating Revenues			0	0
Total Operating Expenses excluding Depreciation and Amortization, and Other (Income) Expense			13,833,063	16,747,739
Depreciation and Amortization			19,670	23,432
Other (Income) Expense			(1,363,915)	1,630,506
Segmented Fixed Assets
Fixed Assets	51,134	39,536	51,134	39,536
Intangible Assets	$ 0	$ 0	$ 0	$ 0